<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2015//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_150101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3080510</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>02</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0091-6749</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>77</Volume>
                    <Issue>1 Pt 1</Issue>
                    <PubDate>
                        <Year>1986</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of allergy and clinical immunology</Title>
                <ISOAbbreviation>J. Allergy Clin. Immunol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Efficacy and safety of astemizole, a long-acting and nonsedating H1 antagonist for the treatment of chronic idiopathic urticaria.</ArticleTitle>
            <Pagination>
                <MedlinePgn>37-42</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The efficacy and safety of astemizole (AST), a new long-acting H1 antagonist with minimal sedative or anticholinergic side effects, were studied in an 8-week double-blind trial of 51 patients with chronic idiopathic urticaria. Patients with chronic idiopathic urticaria were randomized to AST-treated (10 mg every day) or placebo-treated groups. Patients were followed at weekly intervals and evaluated for pruritus, erythema, extent of wheals, frequency of urticarial episodes, and total control of urticaria. Only three of 27 AST-treated patients stopped the double-blind phase before 8 weeks because of inadequate response as compared to 11 of 24 placebo-treated subjects (p = 0.027). On the last evaluable visit of the double-blind phase of the study, 85% of the AST-treated patients reported an excellent or good response compared to 30% of the placebo-treated group (p = 0.0001). AST-treated patients also reported significant improvement compared to placebo-treated patients in pruritus (p = 0.0001), erythema (p = 0.0001), and extent of wheals (p = 0.003). Mild sedative effects were observed in only two of 27 patients receiving AST. It was concluded that AST is a potent and safe drug for symptomatic control of chronic idiopathic urticaria.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Bernstein</LastName>
                    <ForeName>I L</ForeName>
                    <Initials>IL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bernstein</LastName>
                    <ForeName>D I</ForeName>
                    <Initials>DI</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016430">Clinical Trial</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>J Allergy Clin Immunol</MedlineTA>
            <NlmUniqueID>1275002</NlmUniqueID>
            <ISSNLinking>0091-6749</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010919">Placebos</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7HU6337315</RegistryNumber>
                <NameOfSubstance UI="D016589">Astemizole</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016589">Astemizole</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001562">Benzimidazoles</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000592">standards</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002908">Chronic Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002986">Clinical Trials as Topic</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003258">Consumer Behavior</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004311">Double-Blind Method</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010919">Placebos</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014581">Urticaria</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1986</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3080510</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">1493456</PMID>
        <DateCreated>
            <Year>1993</Year>
            <Month>03</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1993</Year>
            <Month>03</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2006</Year>
            <Month>04</Month>
            <Day>24</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1042-8194</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>7 Suppl</Volume>
                    <PubDate>
                        <Year>1992</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Leukemia &amp; lymphoma</Title>
                <ISOAbbreviation>Leuk. Lymphoma</ISOAbbreviation>
            </Journal>
            <ArticleTitle>High-dose chemotherapy with bone marrow rescue for treatment of Hodgkin's disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>29-31</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Between December 1st 1984 and July 1st 1991, 20 patients, 11 males and 9 females, median age 36 years (range 14-54) with Hodgkin's disease were treated with high dose chemo-radiotherapy followed by autologous bone marrow rescue. At the time of autologous bone marrow transplantation, 8 patients were in complete remission, 9 in sensitive relapse and 3 were resistant to conventional treatments. There were 3 early procedure-related deaths: 1 cardiac failure due to cyclophosphamide treatment, 1 veno-occlusive disease, and 1 patient died from CMV interstitial pneumonitis, 4 months after ABMT. Of the 17 other patients, 15 are alive, 12 in complete remission, 2 in relapse and 1 patient is not evaluable due to short-follow-up follow-up. Disease free survival is 65% at 20 months with a follow-up of 60 months. There is a trend for a better disease-free survival in patients in complete remission at the time of autologous bone marrow transplantation vs patients in sensitive relapse, although it does not reach statistical significance (80% vs 37%).</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Sureda</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Bone Marrow Transplantation Group, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brunet</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lopez</LastName>
                    <ForeName>J J</ForeName>
                    <Initials>JJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pardo</LastName>
                    <ForeName>N</ForeName>
                    <Initials>N</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soler</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garcia</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Madoz</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ayats</LastName>
                    <ForeName>R</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mateo</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Domingo-Albos</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>SWITZERLAND</Country>
            <MedlineTA>Leuk Lymphoma</MedlineTA>
            <NlmUniqueID>9007422</NlmUniqueID>
            <ISSNLinking>1026-8022</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000293">Adolescent</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000971">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D016026">Bone Marrow Transplantation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006689">Hodgkin Disease</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000401">mortality</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015996">Survival Rate</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014182">Transplantation, Autologous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014916">Whole-Body Irradiation</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1992</Year>
                <Month>1</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">1493456</ArticleId>
            <ArticleId IdType="doi">10.3109/10428199209061561</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11866297</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>02</Month>
            <Day>27</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>03</Month>
            <Day>14</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9270</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>97</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of gastroenterology</Title>
                <ISOAbbreviation>Am. J. Gastroenterol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clarithromycin use preceding fulminant hepatic failure.</ArticleTitle>
            <Pagination>
                <MedlinePgn>489-90</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Christopher</LastName>
                    <ForeName>Kenneth</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hyatt</LastName>
                    <ForeName>Patrick A</ForeName>
                    <Initials>PA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Horkan</LastName>
                    <ForeName>Clare</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yodice</LastName>
                    <ForeName>Paul C</ForeName>
                    <Initials>PC</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Gastroenterol</MedlineTA>
            <NlmUniqueID>0421030</NlmUniqueID>
            <ISSNLinking>0002-9270</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>H1250JIK0A</RegistryNumber>
                <NameOfSubstance UI="D017291">Clarithromycin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017291">Clarithromycin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007676">Kidney Failure, Chronic</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017093">Liver Failure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006435">Renal Dialysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012141">Respiratory Tract Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018570">Risk Assessment</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>3</Month>
                <Day>15</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>2</Month>
                <Day>28</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11866297</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1572-0241.2002.05505.x</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19289534</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>05</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1479-683X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>160</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of endocrinology / European Federation of Endocrine Societies</Title>
                <ISOAbbreviation>Eur. J. Endocrinol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Merits and pitfalls of mifepristone in Cushing's syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1003-10</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1530/EJE-09-0098</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Mifepristone is the only available glucocorticoid receptor antagonist. Only few adult patients with hypercortisolism were treated to date by this drug. Our objective was to determine effectiveness and tolerability of mifepristone in Cushing's syndrome (CS).</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">Retrospective study of patients treated in seven European centers.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Twenty patients with malignant (n=15, 12 with adrenocortical carcinoma, three with ectopic ACTH secretion) or benign (n=5, four with Cushing's disease, one with bilateral adrenal hyperplasia) CS were treated with mifepristone. Mifepristone was initiated with a median starting dose of 400 mg/day (200-1000). Median treatment duration was 2 months (0.25-21) for malignant CS, and 6 months (0.5-24) for benign CS. Clinical (signs of hypercortisolism, blood pressure, signs of adrenal insufficiency), and biochemical parameters (serum potassium and glucose) were evaluated.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Treatment was stopped in one patient after 1 week due to severe uncontrolled hypokalemia. Improvement of clinical signs was observed in 11/15 patients with malignant CS (73%), and 4/5 patients with benign CS (80%). Psychiatric symptoms improved in 4/5 patients within the first week. Blood glucose levels improved in 4/7 patients. Signs of adrenal insufficiency were observed in 3/20 patients. Moderate to severe hypokalemia was observed in 11/20 patients and increased blood pressure levels in 3/20 patients.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Mifepristone is a rapidly effective treatment of hypercortisolism, but requires close monitoring of potentially severe hypokalemia, hypertension, and clinical signs of adrenal insufficiency. Mifepristone provides a valuable treatment option in patients with severe CS when surgery is unsuccessful or impossible.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Castinetti</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Service d'Endocrinologie, diabète et maladies métaboliques, et Centre de reference des maladies rares d'origine hypophysaires DEFHY, Hôpital de la Timone, Marseille 13005, France. fredcast@umich.edu</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fassnacht</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johanssen</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Terzolo</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bouchard</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chanson</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Do Cao</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morange</LastName>
                    <ForeName>I</ForeName>
                    <Initials>I</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Picó</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ouzounian</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Young</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hahner</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brue</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allolio</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Conte-Devolx</LastName>
                    <ForeName>B</ForeName>
                    <Initials>B</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2009</Year>
                <Month>03</Month>
                <Day>16</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>England</Country>
            <MedlineTA>Eur J Endocrinol</MedlineTA>
            <NlmUniqueID>9423848</NlmUniqueID>
            <ISSNLinking>0804-4643</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>320T6RNW1F</RegistryNumber>
                <NameOfSubstance UI="D015735">Mifepristone</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000309">Adrenal Insufficiency</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003480">Cushing Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007008">Hypokalemia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015735">Mifepristone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012189">Retrospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D055815">Young Adult</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>16</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>3</Month>
                <Day>18</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>3</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">EJE-09-0098</ArticleId>
            <ArticleId IdType="doi">10.1530/EJE-09-0098</ArticleId>
            <ArticleId IdType="pubmed">19289534</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">18396247</PMID>
        <DateCreated>
            <Year>2008</Year>
            <Month>04</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2008</Year>
            <Month>08</Month>
            <Day>12</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1543-5946</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>6</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2008</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of geriatric pharmacotherapy</Title>
                <ISOAbbreviation>Am J Geriatr Pharmacother</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction.</ArticleTitle>
            <Pagination>
                <MedlinePgn>33-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.amjopharm.2008.03.003</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It has been &gt;25 years since the interaction between warfarin and metronidazole was last reported in the literature. The current case report represents the first documentation of this interaction associated with intracerebral hemorrhage.</AbstractText>
                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">We present a case of a 78-year-old white woman started on metronidazole (250 mg every 8 hours for 5 days) and levofloxacin (500 mg QD for 6 days) for an upper respiratory tract infection after visiting a walk-in clinic. The patient did not notify any of the health care professionals involved that she was on concomitant warfarin therapy, which had been stable over the last 3 months. Her warfarin dose was 7 mg daily, and her most recent international normalized ratio (INR) reading was 2.5. Nine days after her clinic visit, the patient was admitted to the hospital for a profuse nosebleed with an INR of 8.0 and was found to have an intraparenchymal hemorrhage of the left occipital lobe. The Naranjo adverse drug reaction probability scale indicated that the association with metronidazole was probable and the association with levofloxacin was possible (scores of 7 and 4, respectively). After a 1-week hospital stay, she was discharged.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This adverse event is highly suggestive of a drug interaction caused primarily by metronidazole, which produces an increase in S-warfarin concentrations. Treatment provided by health care providers who were not familiar with the patient and the use of a different pharmacy (where the pharmacist was unaware of her current medications) likely contributed to the event.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Howard-Thompson</LastName>
                    <ForeName>Amanda</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pharmacy, Methodist University Hospital, Memphis, Tennessee 38104, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hurdle</LastName>
                    <ForeName>April C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Arnold</LastName>
                    <ForeName>Lori B</ForeName>
                    <Initials>LB</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Finch</LastName>
                    <ForeName>Christopher K</ForeName>
                    <Initials>CK</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sands</LastName>
                    <ForeName>Christopher</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Self</LastName>
                    <ForeName>Timothy H</ForeName>
                    <Initials>TH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Am J Geriatr Pharmacother</MedlineTA>
            <NlmUniqueID>101190325</NlmUniqueID>
            <ISSNLinking>1876-7761</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>140QMO216E</RegistryNumber>
                <NameOfSubstance UI="D008795">Metronidazole</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
                <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000890">Anti-Infective Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000925">Anticoagulants</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002543">Cerebral Hemorrhage</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004347">Drug Interactions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019934">International Normalized Ratio</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008795">Metronidazole</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014859">Warfarin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2008</Year>
                <Month>1</Month>
                <Day>3</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2008</Year>
                <Month>8</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2008</Year>
                <Month>4</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S1543-5946(08)00005-6</ArticleId>
            <ArticleId IdType="doi">10.1016/j.amjopharm.2008.03.003</ArticleId>
            <ArticleId IdType="pubmed">18396247</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">3946274</PMID>
        <DateCreated>
            <Year>1986</Year>
            <Month>03</Month>
            <Day>17</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1986</Year>
            <Month>03</Month>
            <Day>17</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9149</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>57</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>1986</Year>
                        <Month>Feb</Month>
                        <Day>15</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The American journal of cardiology</Title>
                <ISOAbbreviation>Am. J. Cardiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Ischemic chest pain after 5-fluorouracil therapy for cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>497-8</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Baker</LastName>
                    <ForeName>W P</ForeName>
                    <Initials>WP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dainer</LastName>
                    <ForeName>P</ForeName>
                    <Initials>P</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lester</LastName>
                    <ForeName>W M</ForeName>
                    <Initials>WM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Marty</LastName>
                    <ForeName>A M</ForeName>
                    <Initials>AM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Blair</LastName>
                    <ForeName>T P</ForeName>
                    <Initials>TP</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Cardiol</MedlineTA>
            <NlmUniqueID>0207277</NlmUniqueID>
            <ISSNLinking>0002-9149</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>U3P01618RT</RegistryNumber>
                <NameOfSubstance UI="D005472">Fluorouracil</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000787">Angina Pectoris</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003331">Coronary Vessels</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005472">Fluorouracil</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006439">Hemodynamics</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1986</Year>
                <Month>2</Month>
                <Day>15</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1986</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1986</Year>
                <Month>2</Month>
                <Day>15</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">3946274</ArticleId>
            <ArticleId IdType="pii">0002-9149(86)90788-5</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24705253</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>01</Month>
            <Day>14</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>De novo CCND2 mutations leading to stabilization of cyclin D2 cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome.</ArticleTitle>
            <Pagination>
                <MedlinePgn>510-5</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2948</ELocationID>
            <Abstract>
                <AbstractText>Activating mutations in genes encoding phosphatidylinositol 3-kinase (PI3K)-AKT pathway components cause megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome (MPPH, OMIM 603387). Here we report that individuals with MPPH lacking upstream PI3K-AKT pathway mutations carry de novo mutations in CCND2 (encoding cyclin D2) that are clustered around a residue that can be phosphorylated by glycogen synthase kinase 3β (GSK-3β). Mutant CCND2 was resistant to proteasomal degradation in vitro compared to wild-type CCND2. The PI3K-AKT pathway modulates GSK-3β activity, and cells from individuals with PIK3CA, PIK3R2 or AKT3 mutations showed similar CCND2 accumulation. CCND2 was expressed at higher levels in brains of mouse embryos expressing activated AKT3. In utero electroporation of mutant CCND2 into embryonic mouse brains produced more proliferating transfected progenitors and a smaller fraction of progenitors exiting the cell cycle compared to cells electroporated with wild-type CCND2. These observations suggest that cyclin D2 stabilization, caused by CCND2 mutation or PI3K-AKT activation, is a unifying mechanism in PI3K-AKT-related megalencephaly syndromes.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mirzaa</LastName>
                    <ForeName>Ghayda M</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA. [2] Department of Pediatrics, University of Washington, Seattle, Washington, USA. [3].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parry</LastName>
                    <ForeName>David A</ForeName>
                    <Initials>DA</Initials>
                    <Identifier Source="ORCID">0000000303767736</Identifier>
                    <AffiliationInfo>
                        <Affiliation>1] Leeds Institute of Biomedical and Clinical Science, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fry</LastName>
                    <ForeName>Andrew E</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Giamanco</LastName>
                    <ForeName>Kristin A</ForeName>
                    <Initials>KA</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Neurogenetics and Development, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, New York, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwartzentruber</LastName>
                    <ForeName>Jeremy</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>McGill University and Genome Quebec Innovation Centre, Montréal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vanstone</LastName>
                    <ForeName>Megan</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Logan</LastName>
                    <ForeName>Clare V</ForeName>
                    <Initials>CV</Initials>
                    <Identifier Source="ORCID">0000000343231602</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Leeds Institute of Biomedical and Clinical Science, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Roberts</LastName>
                    <ForeName>Nicola</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leeds Institute of Biomedical and Clinical Science, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johnson</LastName>
                    <ForeName>Colin A</ForeName>
                    <Initials>CA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leeds Institute of Biomedical and Clinical Science, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Singh</LastName>
                    <ForeName>Shawn</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurogenetics and Development, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kholmanskikh</LastName>
                    <ForeName>Stanislav S</ForeName>
                    <Initials>SS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurogenetics and Development, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adams</LastName>
                    <ForeName>Carissa</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hodge</LastName>
                    <ForeName>Rebecca D</ForeName>
                    <Initials>RD</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA. [2] Department of Neurological Surgery, University of Washington, Seattle, Washington, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hevner</LastName>
                    <ForeName>Robert F</ForeName>
                    <Initials>RF</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA. [2] Department of Neurological Surgery, University of Washington, Seattle, Washington, USA. [3] Department of Pathology, University of Washington, Seattle, Washington, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bonthron</LastName>
                    <ForeName>David T</ForeName>
                    <Initials>DT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leeds Institute of Biomedical and Clinical Science, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Braun</LastName>
                    <ForeName>Kees P J</ForeName>
                    <Initials>KP</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Child Neurology, University Medical Center (UMC) Utrecht, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Faivre</LastName>
                    <ForeName>Laurence</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre de Génétique et Centre de Référence Anomalies du Développement et Syndromes Malformatifs, Hôpital d'Enfants, Centre Hospitalier Universitaire (CHU) Dijon, Université de Bourgogne, Dijon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rivière</LastName>
                    <ForeName>Jean-Baptiste</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université de Bourgogne, Equipe Génétique des Anomalies du Développement (GAD), EA 4271, Dijon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>St-Onge</LastName>
                    <ForeName>Judith</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Université de Bourgogne, Equipe Génétique des Anomalies du Développement (GAD), EA 4271, Dijon, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gripp</LastName>
                    <ForeName>Karen W</ForeName>
                    <Initials>KW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Medical Genetics, A.I. duPont Hospital for Children, Wilmington, Delaware, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mancini</LastName>
                    <ForeName>Grazia M S</ForeName>
                    <Initials>GM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Genetics and Expertise Centre for Neurodevelopmental Disorders, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pang</LastName>
                    <ForeName>Ki</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Paediatric Neurology, Royal Victoria Infirmary, Newcastle upon Tyne, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sweeney</LastName>
                    <ForeName>Elizabeth</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Clinical Genetics, Liverpool Women's National Health Service (NHS) Foundation Trust, Liverpool, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>van Esch</LastName>
                    <ForeName>Hilde</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre for Human Genetics, University Hospital Gasthuisberg, Herestraat, Leuven, Belgium.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Verbeek</LastName>
                    <ForeName>Nienke</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Genetics, UMC Utrecht, Utrecht, The Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wieczorek</LastName>
                    <ForeName>Dagmar</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institut fur Humangenetik, Universitatsklinikum Essen, Essen, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Steinraths</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Majewski</LastName>
                    <ForeName>Jacek</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>McGill University and Genome Quebec Innovation Centre, Montréal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>FORGE Canada Consortium</CollectiveName>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boycott</LastName>
                    <ForeName>Kym M</ForeName>
                    <Initials>KM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pilz</LastName>
                    <ForeName>Daniela T</ForeName>
                    <Initials>DT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Medical Genetics, University Hospital of Wales, Cardiff, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ross</LastName>
                    <ForeName>M Elizabeth</ForeName>
                    <Initials>ME</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neurogenetics and Development, Feil Family Brain and Mind Research Institute, Weill Cornell Medical College, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dobyns</LastName>
                    <ForeName>William B</ForeName>
                    <Initials>WB</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Center for Integrative Brain Research, Seattle Children's Research Institute, Seattle, Washington, USA. [2] Department of Pediatrics, University of Washington, Seattle, Washington, USA. [3] Department of Neurology, University of Washington, Seattle, Washington, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sheridan</LastName>
                    <ForeName>Eamonn G</ForeName>
                    <Initials>EG</Initials>
                    <AffiliationInfo>
                        <Affiliation>Leeds Institute of Biomedical and Clinical Science, Wellcome Trust Brenner Building, St. James's University Hospital, Leeds, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>F32 NS086173</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>F32 NS086173</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MR/K011154/1</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>OGI-049</GrantID>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 NS048120</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01-NS048120</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 NS058721</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01NS058721</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C080336">CCND2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D056742">Cyclin D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>G34N38R2N1</RegistryNumber>
                <NameOfSubstance UI="D001973">Bromodeoxyuridine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2001 Oct;2(10):769-76</RefSource>
                <PMID Version="1">11584304</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Development. 1999 May;126(9):1927-35</RefSource>
                <PMID Version="1">10101126</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 2005 Jan 5;25(1):247-51</RefSource>
                <PMID Version="1">15634788</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurosci Res. 2006 Jul;55(3):223-33</RefSource>
                <PMID Version="1">16621079</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cereb Cortex. 2006 Jul;16 Suppl 1:i152-61</RefSource>
                <PMID Version="1">16766701</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cereb Cortex. 2007 Mar;17(3):632-42</RefSource>
                <PMID Version="1">16627858</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2007 Apr;39(4):454-6</RefSource>
                <PMID Version="1">17353897</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2007 Oct 11;26(46):6630-40</RefSource>
                <PMID Version="1">17486076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Development. 2007 Nov;134(22):4083-93</RefSource>
                <PMID Version="1">17965053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Neurosci. 2008;30(1-3):24-32</RefSource>
                <PMID Version="1">18075251</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Neurosci. 2008 Feb;9(2):110-22</RefSource>
                <PMID Version="1">18209730</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Jul 15;25(14):1754-60</RefSource>
                <PMID Version="1">19451168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci. 2009 Jul 29;29(30):9614-24</RefSource>
                <PMID Version="1">19641124</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Aug 15;25(16):2078-9</RefSource>
                <PMID Version="1">19505943</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2010 Sep;20(9):1297-303</RefSource>
                <PMID Version="1">20644199</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2010 Sep;38(16):e164</RefSource>
                <PMID Version="1">20601685</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2011 Mar 1;20(5):988-99</RefSource>
                <PMID Version="1">21159799</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2011 May;43(5):491-8</RefSource>
                <PMID Version="1">21478889</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuron. 2012 Apr 12;74(1):41-8</RefSource>
                <PMID Version="1">22500628</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):928-33</RefSource>
                <PMID Version="1">22729222</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):941-5</RefSource>
                <PMID Version="1">22729223</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Aug;44(8):934-40</RefSource>
                <PMID Version="1">22729224</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2012 Jul;9(7):671-5</RefSource>
                <PMID Version="1">22930834</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EMBO J. 2013 Jul 3;32(13):1817-28</RefSource>
                <PMID Version="1">23624932</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000015">Abnormalities, Multiple</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015153">Blotting, Western</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001973">Bromodeoxyuridine</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056742">Cyclin D2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018274">Electroporation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006849">Hydrocephalus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D054220">Malformations of Cortical Development</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058627">Megalencephaly</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008856">Microscopy, Fluorescence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016297">Mutagenesis, Site-Directed</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017689">Polydactyly</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS575218</OtherID>
        <OtherID Source="NLM">PMC4004933</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>12</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2948</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2948</ArticleId>
            <ArticleId IdType="pubmed">24705253</ArticleId>
            <ArticleId IdType="pmc">PMC4004933</ArticleId>
            <ArticleId IdType="mid">NIHMS575218</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24705254</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations.</ArticleTitle>
            <Pagination>
                <MedlinePgn>451-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2936</ELocationID>
            <Abstract>
                <AbstractText>Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Buczkowicz</LastName>
                    <ForeName>Pawel</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Pathology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. [2] Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. [3] Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. [4].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hoeman</LastName>
                    <ForeName>Christine</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, North Carolina, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rakopoulos</LastName>
                    <ForeName>Patricia</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. [2] Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pajovic</LastName>
                    <ForeName>Sanja</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Letourneau</LastName>
                    <ForeName>Louis</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dzamba</LastName>
                    <ForeName>Misko</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computer Science, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morrison</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lewis</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Chromatin Biology and Epigenetics, Rockefeller University, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bouffet</LastName>
                    <ForeName>Eric</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bartels</LastName>
                    <ForeName>Ute</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zuccaro</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Agnihotri</LastName>
                    <ForeName>Sameer</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ryall</LastName>
                    <ForeName>Scott</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Barszczyk</LastName>
                    <ForeName>Mark</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. [2] Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chornenkyy</LastName>
                    <ForeName>Yevgen</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. [2] Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourgey</LastName>
                    <ForeName>Mathieu</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bourque</LastName>
                    <ForeName>Guillaume</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Montpetit</LastName>
                    <ForeName>Alexandre</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Génome Québec Innovation Centre, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cordero</LastName>
                    <ForeName>Francisco</ForeName>
                    <Initials>F</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, North Carolina, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castelo-Branco</LastName>
                    <ForeName>Pedro</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mangerel</LastName>
                    <ForeName>Joshua</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tabori</LastName>
                    <ForeName>Uri</ForeName>
                    <Initials>U</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. [2] Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ho</LastName>
                    <ForeName>King Ching</ForeName>
                    <Initials>KC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Annie</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. [2] Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taylor</LastName>
                    <ForeName>Kathryn R</ForeName>
                    <Initials>KR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Therapeutics, Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mackay</LastName>
                    <ForeName>Alan</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Therapeutics, Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bendel</LastName>
                    <ForeName>Anne E</ForeName>
                    <Initials>AE</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Hematology-Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nazarian</LastName>
                    <ForeName>Javad</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Genetic Medicine, Children's National Medical Center, Washington, DC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fangusaro</LastName>
                    <ForeName>Jason R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics-Hematology, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karajannis</LastName>
                    <ForeName>Matthias A</ForeName>
                    <Initials>MA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Hematology/Oncology and Neuropathology, New York University Cancer Institute, New York University Langone Medical Center, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zagzag</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Hematology/Oncology and Neuropathology, New York University Cancer Institute, New York University Langone Medical Center, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Foreman</LastName>
                    <ForeName>Nicholas K</ForeName>
                    <Initials>NK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Children's Hospital Colorado, Denver, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Donson</LastName>
                    <ForeName>Andrew</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Children's Hospital Colorado, Denver, Colorado, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hegert</LastName>
                    <ForeName>Julia V</ForeName>
                    <Initials>JV</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Arnold Palmer Hospital for Children, Orlando, Florida, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Smith</LastName>
                    <ForeName>Amy</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Arnold Palmer Hospital for Children, Orlando, Florida, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chan</LastName>
                    <ForeName>Jennifer</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clark H. Smith Brain Tumour Centre, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lafay-Cousin</LastName>
                    <ForeName>Lucy</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clark H. Smith Brain Tumour Centre, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dunn</LastName>
                    <ForeName>Sandra</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Neurology and Neuro-Oncology, BC Children's Hospital, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hukin</LastName>
                    <ForeName>Juliette</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Neurology and Neuro-Oncology, BC Children's Hospital, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dunham</LastName>
                    <ForeName>Chris</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Neurology and Neuro-Oncology, BC Children's Hospital, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Scheinemann</LastName>
                    <ForeName>Katrin</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Hematology/Oncology, McMaster Children's Hospital, Hamilton, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Michaud</LastName>
                    <ForeName>Jean</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology and Laboratory Medicine, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zelcer</LastName>
                    <ForeName>Shayna</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology/Oncology, Children's Hospital London Health Sciences Centre, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramsay</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology/Oncology, Children's Hospital London Health Sciences Centre, London, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cain</LastName>
                    <ForeName>Jason</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Monash Institute of Medical Research, Monash Medical Centre, Clayton, Victoria, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brennan</LastName>
                    <ForeName>Cameron</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Souweidane</LastName>
                    <ForeName>Mark M</ForeName>
                    <Initials>MM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, Weill Cornell Medical College and Memorial Sloan-Kettering Cancer Center, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>Chris</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Cancer Therapeutics, Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Allis</LastName>
                    <ForeName>C David</ForeName>
                    <Initials>CD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Laboratory of Chromatin Biology and Epigenetics, Rockefeller University, New York, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Brudno</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Computer Science, University of Toronto, Toronto, Ontario, Canada. [2] The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, Ontario, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Becher</LastName>
                    <ForeName>Oren</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Pediatric Hematology/Oncology, Duke University Medical Center, Durham, North Carolina, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hawkins</LastName>
                    <ForeName>Cynthia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Pathology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada. [2] Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. [3] Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. [4].</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GEO</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>GSE50021</AccessionNumber>
                        <AccessionNumber>GSE50022</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>115004-1</GrantID>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
                <Grant>
                    <GrantID>5P30CA016087-32</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>MOP 115004</GrantID>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA016087</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA060553</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>T32 HD040372</GrantID>
                    <Acronym>HD</Acronym>
                    <Agency>NICHD NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>UL1TR000038</GrantID>
                    <Acronym>TR</Acronym>
                    <Agency>NCATS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497453">ID1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497450">ID2 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051798">Inhibitor of Differentiation Protein 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051797">Inhibitor of Differentiation Protein 2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051785">Smad Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="C425423">ACVR1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="D030201">Activin Receptors, Type I</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2011 Jun;21(6):830-9</RefSource>
                <PMID Version="1">21460062</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2011 Oct 20;29(30):3999-4006</RefSource>
                <PMID Version="1">21931021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Feb 9;482(7384):226-31</RefSource>
                <PMID Version="1">22286061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):251-3</RefSource>
                <PMID Version="1">22286216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosci Res. 2012 May;90(5):925-32</RefSource>
                <PMID Version="1">22253220</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2012 Apr 6;420(2):281-7</RefSource>
                <PMID Version="1">22421219</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Biochim Biophys Sin (Shanghai). 2012 Jun;44(6):503-12</RefSource>
                <PMID Version="1">22551584</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2012 Jul;40(Web Server issue):W615-21</RefSource>
                <PMID Version="1">22638571</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Neuropathol. 2012 Sep;124(3):439-47</RefSource>
                <PMID Version="1">22661320</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2012 Oct 15;28(20):2576-83</RefSource>
                <PMID Version="1">22851530</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Bone Miner Metab. 2013 Jan;31(1):34-43</RefSource>
                <PMID Version="1">22976053</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Pathol. 2013 May;23(3):244-53</RefSource>
                <PMID Version="1">22971244</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Anticancer Res. 2013 May;33(5):2179-83</RefSource>
                <PMID Version="1">23645773</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Childs Nerv Syst. 1999 Oct;15(10):545-53</RefSource>
                <PMID Version="1">10550585</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 2000 May 27;320(7247):1468</RefSource>
                <PMID Version="1">10827061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2004 May;24(10):4241-54</RefSource>
                <PMID Version="1">15121845</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Child Neurol. 1993 Apr;8(2):112-28</RefSource>
                <PMID Version="1">8505473</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMJ. 1994 Dec 17;309(6969):1612-6</RefSource>
                <PMID Version="1">7819936</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lancet Oncol. 2006 Mar;7(3):241-8</RefSource>
                <PMID Version="1">16510333</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2006 Mar 10;24(8):1266-72</RefSource>
                <PMID Version="1">16525181</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cancer. 2007;6:36</RefSource>
                <PMID Version="1">17547775</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Protoc Cell Biol. 2003 Nov;Chapter 18:Unit 18.6</RefSource>
                <PMID Version="1">18228424</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2009;4(1):e4158</RefSource>
                <PMID Version="1">19129913</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2009 Mar;30(3):379-90</RefSource>
                <PMID Version="1">19085907</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2009;4(3):e5005</RefSource>
                <PMID Version="1">19330033</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2009 Dec;27(12):1181-5</RefSource>
                <PMID Version="1">19935656</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2010 Mar 1;26(5):589-95</RefSource>
                <PMID Version="1">20080505</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2010 Mar 10;28(8):1337-44</RefSource>
                <PMID Version="1">20142589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2010 Jun 20;28(18):3061-8</RefSource>
                <PMID Version="1">20479398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2010 Jul 16;285(29):22542-53</RefSource>
                <PMID Version="1">20463014</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2010 Nov;20(11):1613-22</RefSource>
                <PMID Version="1">20805290</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 May;46(5):421-2</RefSource>
                <PMID Version="1">24769718</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Clin Oncol. 2014 Jun;11(6):300</RefSource>
                <PMID Version="1">24840074</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D030201">Activin Receptors, Type I</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020295">Brain Stem Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056915">DNA Copy Number Variations</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019175">DNA Methylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051798">Inhibitor of Differentiation Protein 1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051797">Inhibitor of Differentiation Protein 2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051785">Smad Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">CAMS4215</OtherID>
        <OtherID Source="NLM">PMC3997489</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>24</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>05</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2936</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2936</ArticleId>
            <ArticleId IdType="pubmed">24705254</ArticleId>
            <ArticleId IdType="pmc">PMC3997489</ArticleId>
            <ArticleId IdType="mid">CAMS4215</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17495388</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>05</Month>
            <Day>14</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>09</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0022-3859</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>53</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <MedlineDate>2007 Apr-Jun</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of postgraduate medicine</Title>
                <ISOAbbreviation>J Postgrad Med</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Successful treatment of palmar-plantar erythrodysesthesia possibly due to temozolomide with dexamethasone.</ArticleTitle>
            <Pagination>
                <MedlinePgn>146</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Kanat</LastName>
                    <ForeName>O</ForeName>
                    <Initials>O</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baskan</LastName>
                    <ForeName>B E</ForeName>
                    <Initials>BE</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kurt</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Evrensel</LastName>
                    <ForeName>T</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016422">Letter</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>J Postgrad Med</MedlineTA>
            <NlmUniqueID>2985196R</NlmUniqueID>
            <ISSNLinking>0022-3859</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018906">Antineoplastic Agents, Alkylating</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7GR28W0FJI</RegistryNumber>
                <NameOfSubstance UI="D003606">Dacarbazine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7S5I7G3JQL</RegistryNumber>
                <NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>85622-93-1</RegistryNumber>
                <NameOfSubstance UI="C047246">temozolomide</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000169">Acrodermatitis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000893">Anti-Inflammatory Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018906">Antineoplastic Agents, Alkylating</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003606">Dacarbazine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003907">Dexamethasone</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003875">Drug Eruptions</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004890">Erythema</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005938">Glucocorticoids</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010292">Paresthesia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>9</Month>
                <Day>5</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">17495388</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24705251</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>12</Month>
            <Day>18</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>444-50</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2938</ELocationID>
            <Abstract>
                <AbstractText>Pediatric high-grade glioma (HGG) is a devastating disease with a less than 20% survival rate 2 years after diagnosis. We analyzed 127 pediatric HGGs, including diffuse intrinsic pontine gliomas (DIPGs) and non-brainstem HGGs (NBS-HGGs), by whole-genome, whole-exome and/or transcriptome sequencing. We identified recurrent somatic mutations in ACVR1 exclusively in DIPGs (32%), in addition to previously reported frequent somatic mutations in histone H3 genes, TP53 and ATRX, in both DIPGs and NBS-HGGs. Structural variants generating fusion genes were found in 47% of DIPGs and NBS-HGGs, with recurrent fusions involving the neurotrophin receptor genes NTRK1, NTRK2 and NTRK3 in 40% of NBS-HGGs in infants. Mutations targeting receptor tyrosine kinase-RAS-PI3K signaling, histone modification or chromatin remodeling, and cell cycle regulation were found in 68%, 73% and 59% of pediatric HGGs, respectively, including in DIPGs and NBS-HGGs. This comprehensive analysis provides insights into the unique and shared pathways driving pediatric HGG within and outside the brainstem.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Gang</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Diaz</LastName>
                    <ForeName>Alexander K</ForeName>
                    <Initials>AK</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [2] Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, Tennessee, USA. [3].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Paugh</LastName>
                    <ForeName>Barbara S</ForeName>
                    <Initials>BS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rankin</LastName>
                    <ForeName>Sherri L</ForeName>
                    <Initials>SL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ju</LastName>
                    <ForeName>Bensheng</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Yongjin</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhu</LastName>
                    <ForeName>Xiaoyan</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qu</LastName>
                    <ForeName>Chunxu</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chen</LastName>
                    <ForeName>Xiang</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Junyuan</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Easton</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Cancer Genome Project, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Edmonson</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ma</LastName>
                    <ForeName>Xiaotu</ForeName>
                    <Initials>X</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lu</LastName>
                    <ForeName>Charles</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Genome Institute, Washington University, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagahawatte</LastName>
                    <ForeName>Panduka</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hedlund</LastName>
                    <ForeName>Erin</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rusch</LastName>
                    <ForeName>Michael</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pounds</LastName>
                    <ForeName>Stanley</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Tong</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Onar-Thomas</LastName>
                    <ForeName>Arzu</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huether</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kriwacki</LastName>
                    <ForeName>Richard</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Structural Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Parker</LastName>
                    <ForeName>Matthew</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Pankaj</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Becksfort</LastName>
                    <ForeName>Jared</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wei</LastName>
                    <ForeName>Lei</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, New York, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mulder</LastName>
                    <ForeName>Heather L</ForeName>
                    <Initials>HL</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Cancer Genome Project, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boggs</LastName>
                    <ForeName>Kristy</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Cancer Genome Project, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vadodaria</LastName>
                    <ForeName>Bhavin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Cancer Genome Project, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yergeau</LastName>
                    <ForeName>Donald</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Cancer Genome Project, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Russell</LastName>
                    <ForeName>Jake C</ForeName>
                    <Initials>JC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ochoa</LastName>
                    <ForeName>Kerri</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Genome Institute, Washington University, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fulton</LastName>
                    <ForeName>Robert S</ForeName>
                    <Initials>RS</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Genome Institute, Washington University, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fulton</LastName>
                    <ForeName>Lucinda L</ForeName>
                    <Initials>LL</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Genome Institute, Washington University, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>Chris</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Molecular Pathology, Institute for Cancer Research, London, UK. [2] Divison of Cancer Therapeutics, Institute for Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Boop</LastName>
                    <ForeName>Frederick A</ForeName>
                    <Initials>FA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Surgery, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Broniscer</LastName>
                    <ForeName>Alberto</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wetmore</LastName>
                    <ForeName>Cynthia</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gajjar</LastName>
                    <ForeName>Amar</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ding</LastName>
                    <ForeName>Li</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Genome Institute, Washington University, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mardis</LastName>
                    <ForeName>Elaine R</ForeName>
                    <Initials>ER</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Genome Institute, Washington University, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wilson</LastName>
                    <ForeName>Richard K</ForeName>
                    <Initials>RK</Initials>
                    <AffiliationInfo>
                        <Affiliation>The Genome Institute, Washington University, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Taylor</LastName>
                    <ForeName>Michael R</ForeName>
                    <Initials>MR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Chemical Biology and Therapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Downing</LastName>
                    <ForeName>James R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ellison</LastName>
                    <ForeName>David W</ForeName>
                    <Initials>DW</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jinghui</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Baker</LastName>
                    <ForeName>Suzanne J</ForeName>
                    <Initials>SJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Developmental Neurobiology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. [2] Integrated Biomedical Sciences Program, University of Tennessee Health Science Center, Memphis, Tennessee, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <CollectiveName>St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project</CollectiveName>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P01 CA096832</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P01 CA096832</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA021765</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA135554</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>R01 CA135554</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020917">Receptor, trkA</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020813">Receptor, trkB</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.10.1</RegistryNumber>
                <NameOfSubstance UI="D020812">Receptor, trkC</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="C425423">ACVR1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="D030201">Activin Receptors, Type I</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2007 Apr 1;25(10):1196-208</RefSource>
                <PMID Version="1">17401009</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2007 Nov;27(22):7918-34</RefSource>
                <PMID Version="1">17875932</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2007 Dec;12(6):542-58</RefSource>
                <PMID Version="1">18068631</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2008 Jan;13(1):69-80</RefSource>
                <PMID Version="1">18167341</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Dev. 2008 Mar 15;22(6):722-7</RefSource>
                <PMID Version="1">18347090</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2012 Sep 28;151(1):68-79</RefSource>
                <PMID Version="1">23021216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2012 Oct 16;22(4):425-37</RefSource>
                <PMID Version="1">23079654</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Child Neurol. 2008 Oct;23(10):1149-59</RefSource>
                <PMID Version="1">18952581</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Jul 15;25(14):1754-60</RefSource>
                <PMID Version="1">19451168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2009 Sep 15;15(18):5753-61</RefSource>
                <PMID Version="1">19737945</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2009 Oct 1;15(19):5962-7</RefSource>
                <PMID Version="1">19755385</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2009 Nov;119(11):3462-72</RefSource>
                <PMID Version="1">19855136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2008 Sep 26;321(5897):1807-12</RefSource>
                <PMID Version="1">18772396</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2008 Oct 23;455(7216):1061-8</RefSource>
                <PMID Version="1">18772890</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2011 Jan 7;144(1):27-40</RefSource>
                <PMID Version="1">21215367</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuro Oncol. 2011 Feb;13(2):212-22</RefSource>
                <PMID Version="1">21138945</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Osteoporos Rep. 2011 Jun;9(2):83-8</RefSource>
                <PMID Version="1">21340697</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2011 Jun 15;71(12):4106-16</RefSource>
                <PMID Version="1">21507933</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Methods. 2011 Aug;8(8):652-4</RefSource>
                <PMID Version="1">21666668</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2011 Aug 4;30(31):3391-403</RefSource>
                <PMID Version="1">21516126</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2011 Oct 20;29(30):3999-4006</RefSource>
                <PMID Version="1">21931021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jan 12;481(7380):157-63</RefSource>
                <PMID Version="1">22237106</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Jan 19;481(7381):329-34</RefSource>
                <PMID Version="1">22237022</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Feb 9;482(7384):226-31</RefSource>
                <PMID Version="1">22286061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2012 Feb 14;21(2):168-80</RefSource>
                <PMID Version="1">22340591</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):251-3</RefSource>
                <PMID Version="1">22286216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(2):e30313</RefSource>
                <PMID Version="1">22389665</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurooncol. 2012 Jul;108(3):395-402</RefSource>
                <PMID Version="1">22382786</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Neurobiol. 2012 Jul;72(7):1068-84</RefSource>
                <PMID Version="1">22489086</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Aug 2;488(7409):43-8</RefSource>
                <PMID Version="1">22722829</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Aug 2;488(7409):100-5</RefSource>
                <PMID Version="1">22832583</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Aug 2;488(7409):106-10</RefSource>
                <PMID Version="1">22820256</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Neuropathol. 2012 Sep;124(3):439-47</RefSource>
                <PMID Version="1">22661320</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2012 Sep 28;151(1):56-67</RefSource>
                <PMID Version="1">23021215</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2010 Jan 15;70(2):512-9</RefSource>
                <PMID Version="1">20068183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuro Oncol. 2010 Feb;12(2):153-63</RefSource>
                <PMID Version="1">20150382</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2010 Mar 10;28(8):1337-44</RefSource>
                <PMID Version="1">20142589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Neurobiol. 2010 Apr;70(5):298-303</RefSource>
                <PMID Version="1">20186708</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2010 Jun 20;28(18):3061-8</RefSource>
                <PMID Version="1">20479398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2010 Jul 1;16(13):3368-77</RefSource>
                <PMID Version="1">20570930</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Pharmacol. 2010 Sep;161(1):140-9</RefSource>
                <PMID Version="1">20718746</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2012 Oct 26;287(44):36990-8</RefSource>
                <PMID Version="1">22977237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Neuropathol. 2013 Mar;125(3):373-84</RefSource>
                <PMID Version="1">23184418</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Mar;45(3):242-52</RefSource>
                <PMID Version="1">23334668</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2013 Mar 14;152(6):1226-36</RefSource>
                <PMID Version="1">23498933</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2013 Apr 9;110(15):6021-6</RefSource>
                <PMID Version="1">23530248</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Neuropathol. 2013 May;125(5):659-69</RefSource>
                <PMID Version="1">23417712</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genes Dev. 2013 May 1;27(9):985-90</RefSource>
                <PMID Version="1">23603901</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Cell Biol. 2013 May 13;201(4):511-21</RefSource>
                <PMID Version="1">23649806</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2013 May 17;340(6134):857-61</RefSource>
                <PMID Version="1">23539183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2013 Jun;33(12):2413-24</RefSource>
                <PMID Version="1">23572558</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Jun;45(6):602-12</RefSource>
                <PMID Version="1">23583981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Aug;45(8):927-32</RefSource>
                <PMID Version="1">23817572</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Pathol. 2013 Sep;23(5):558-64</RefSource>
                <PMID Version="1">23414300</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Oct;45(10):1141-9</RefSource>
                <PMID Version="1">23917401</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2013 Sep 27;288(39):27940-50</RefSource>
                <PMID Version="1">23798677</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2013 Nov 11;24(5):660-72</RefSource>
                <PMID Version="1">24183680</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2001 Oct 15;61(20):7404-7</RefSource>
                <PMID Version="1">11606370</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2001 Dec;29(4):418-25</RefSource>
                <PMID Version="1">11694875</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Cell Biol. 2002 Jul;22(14):5100-13</RefSource>
                <PMID Version="1">12077339</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Biotechnol. 2004 May;22(5):589-94</RefSource>
                <PMID Version="1">15064769</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genomics. 1995 Jul 1;28(1):15-24</RefSource>
                <PMID Version="1">7590742</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 1998 Mar;8(3):195-202</RefSource>
                <PMID Version="1">9521923</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1999 Jan 15;93(2):488-99</RefSource>
                <PMID Version="1">9885210</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Blood. 1999 Feb 15;93(4):1355-63</RefSource>
                <PMID Version="1">9949179</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Res. 2004 Nov 1;64(21):7773-9</RefSource>
                <PMID Version="1">15520182</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Cancer Biol. 2005 Jun;15(3):215-23</RefSource>
                <PMID Version="1">15826836</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Comput Biol. 2005 Oct;1(5):e53</RefSource>
                <PMID Version="1">16261194</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 May;38(5):525-7</RefSource>
                <PMID Version="1">16642017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2006 Dec 7;444(7120):761-5</RefSource>
                <PMID Version="1">17151667</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 May;46(5):421-2</RefSource>
                <PMID Version="1">24769718</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Clin Oncol. 2014 Jun;11(6):300</RefSource>
                <PMID Version="1">24840074</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D030201">Activin Receptors, Type I</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020295">Brain Stem Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019295">Computational Biology</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020869">Gene Expression Profiling</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050939">Gene Fusion</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015151">Immunoblotting</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D046228">Microarray Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020917">Receptor, trkA</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020813">Receptor, trkB</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020812">Receptor, trkC</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020133">Reverse Transcriptase Polymerase Chain Reaction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018709">Statistics, Nonparametric</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015027">Zebrafish</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS573627</OtherID>
        <OtherID Source="NLM">PMC4056452</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2938</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2938</ArticleId>
            <ArticleId IdType="pubmed">24705251</ArticleId>
            <ArticleId IdType="pmc">PMC4056452</ArticleId>
            <ArticleId IdType="mid">NIHMS573627</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24705252</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>11</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>457-61</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2925</ELocationID>
            <Abstract>
                <AbstractText>Diffuse intrinsic pontine gliomas (DIPGs) are highly infiltrative malignant glial neoplasms of the ventral pons that, due to their location within the brain, are unsuitable for surgical resection and consequently have a universally dismal clinical outcome. The median survival time is 9-12 months, with neither chemotherapeutic nor targeted agents showing substantial survival benefit in clinical trials in children with these tumors. We report the identification of recurrent activating mutations in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, in 21% of DIPG samples. Strikingly, these somatic mutations (encoding p.Arg206His, p.Arg258Gly, p.Gly328Glu, p.Gly328Val, p.Gly328Trp and p.Gly356Asp substitutions) have not been reported previously in cancer but are identical to mutations found in the germ line of individuals with the congenital childhood developmental disorder fibrodysplasia ossificans progressiva (FOP) and have been shown to constitutively activate the BMP-TGF-β signaling pathway. These mutations represent new targets for therapeutic intervention in this otherwise incurable disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Taylor</LastName>
                    <ForeName>Kathryn R</ForeName>
                    <Initials>KR</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Institute of Cancer Research, London, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mackay</LastName>
                    <ForeName>Alan</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Institute of Cancer Research, London, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Truffaux</LastName>
                    <ForeName>Nathalène</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNRS UMR 8203, Gustave Roussy, University Paris Sud, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Butterfield</LastName>
                    <ForeName>Yaron S</ForeName>
                    <Initials>YS</Initials>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Morozova</LastName>
                    <ForeName>Olena</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Biomolecular Engineering, University of California, Santa Cruz, Santa Cruz, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Philippe</LastName>
                    <ForeName>Cathy</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNRS UMR 8203, Gustave Roussy, University Paris Sud, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castel</LastName>
                    <ForeName>David</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNRS UMR 8203, Gustave Roussy, University Paris Sud, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grasso</LastName>
                    <ForeName>Catherine S</ForeName>
                    <Initials>CS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Molecular and Medical Genetics, Oregon Health and Science University, Portland, Oregon, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Vinci</LastName>
                    <ForeName>Maria</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carvalho</LastName>
                    <ForeName>Diana</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carcaboso</LastName>
                    <ForeName>Angel M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Torres</LastName>
                    <ForeName>Carmen</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cruz</LastName>
                    <ForeName>Ofelia</ForeName>
                    <Initials>O</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mora</LastName>
                    <ForeName>Jaume</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Hematology and Oncology, Hospital Sant Joan de Déu, Barcelona, Spain.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Entz-Werle</LastName>
                    <ForeName>Natacha</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Centre Hospitalier Regional et Universitaire Hautepierre, Strasbourg, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ingram</LastName>
                    <ForeName>Wendy J</ForeName>
                    <Initials>WJ</Initials>
                    <AffiliationInfo>
                        <Affiliation>Queensland Children's Tumour Bank, Queensland Children's Medical Research Institute, The University of Queensland, Brisbane, Queensland, Australia.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Monje</LastName>
                    <ForeName>Michelle</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hargrave</LastName>
                    <ForeName>Darren</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neuro-oncology and Experimental Therapeutics, Great Ormond Street Hospital, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bullock</LastName>
                    <ForeName>Alex N</ForeName>
                    <Initials>AN</Initials>
                    <AffiliationInfo>
                        <Affiliation>Structural Genomics Consortium, University of Oxford, Oxford, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Puget</LastName>
                    <ForeName>Stéphanie</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Neurosurgery, Necker Sick Children's Hospital, Paris, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yip</LastName>
                    <ForeName>Stephen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>BC Cancer Agency, Vancouver, British Columbia, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>Chris</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Cancer Research, London, UK.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grill</LastName>
                    <ForeName>Jacques</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>CNRS UMR 8203, Gustave Roussy, University Paris Sud, Villejuif, France.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>092809</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>092809/Z/10/Z</GrantID>
                    <Agency>Wellcome Trust</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>A13982</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>A14078</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>A14078</GrantID>
                    <Agency>Cancer Research UK</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
                <Grant>
                    <GrantID>K08NS070926</GrantID>
                    <Acronym>NS</Acronym>
                    <Agency>NINDS NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="C425423">ACVR1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="D030201">Activin Receptors, Type I</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Chem Biol. 2008 Jan;4(1):33-41</RefSource>
                <PMID Version="1">18026094</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurosurg. 2007 Jul;107(1 Suppl):1-4</RefSource>
                <PMID Version="1">17647306</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 2008 Dec;14(12):1363-9</RefSource>
                <PMID Version="1">19029982</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Hum Genet. 2009 Mar;17(3):311-8</RefSource>
                <PMID Version="1">18830232</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2009 Mar;30(3):379-90</RefSource>
                <PMID Version="1">19085907</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2009;4(3):e5005</RefSource>
                <PMID Version="1">19330033</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Rheumatol. 2010 Sep;6(9):518-27</RefSource>
                <PMID Version="1">20703219</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50</RefSource>
                <PMID Version="1">20952405</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2011 Oct 20;29(30):3999-4006</RefSource>
                <PMID Version="1">21931021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Feb 9;482(7384):226-31</RefSource>
                <PMID Version="1">22286061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):251-3</RefSource>
                <PMID Version="1">22286216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2012;7(2):e30313</RefSource>
                <PMID Version="1">22389665</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Clin Oncol. 2012 Jul;9(7):400-13</RefSource>
                <PMID Version="1">22641364</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2012 Oct 26;287(44):36990-8</RefSource>
                <PMID Version="1">22977237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurol. 2012 Dec;259(12):2644-55</RefSource>
                <PMID Version="1">22736080</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2013 May 17;340(6134):857-61</RefSource>
                <PMID Version="1">23539183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2008 Dec 19;377(3):905-9</RefSource>
                <PMID Version="1">18952055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Br J Anaesth. 2006 Nov;97(5):701-3</RefSource>
                <PMID Version="1">17003066</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 May;38(5):525-7</RefSource>
                <PMID Version="1">16642017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 May;46(5):421-2</RefSource>
                <PMID Version="1">24769718</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Clin Oncol. 2014 Jun;11(6):300</RefSource>
                <PMID Version="1">24840074</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D030201">Activin Receptors, Type I</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020295">Brain Stem Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015331">Cohort Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D059472">Exome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005910">Glioma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000145">classification</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020125">Mutation, Missense</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009221">Myositis Ossificans</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">EMS57117</OtherID>
        <OtherID Source="NLM">PMC4018681</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>4</Month>
                <Day>30</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>2</Month>
                <Day>21</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2925</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2925</ArticleId>
            <ArticleId IdType="pubmed">24705252</ArticleId>
            <ArticleId IdType="pmc">PMC4018681</ArticleId>
            <ArticleId IdType="mid">EMS57117</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11940710</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>04</Month>
            <Day>09</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>05</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2004</Year>
            <Month>11</Month>
            <Day>17</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0028-3878</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>58</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Apr</Month>
                        <Day>9</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Neurology</Title>
                <ISOAbbreviation>Neurology</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Brown-Sequard syndrome after esophageal sclerotherapy and crack cocaine abuse.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1129-30</MedlinePgn>
            </Pagination>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Mueller</LastName>
                    <ForeName>Deborah</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, University of Colorado Health Sciences Center, Denver 80262, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gilden</LastName>
                    <ForeName>Donald H</ForeName>
                    <Initials>DH</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Neurology</MedlineTA>
            <NlmUniqueID>0401060</NlmUniqueID>
            <ISSNLinking>0028-3878</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D016578">Crack Cocaine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018437">Brown-Sequard Syndrome</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019970">Cocaine-Related Disorders</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016578">Crack Cocaine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004945">Esophagoscopy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015911">Sclerotherapy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013904">Thoracic Vertebrae</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>5</Month>
                <Day>8</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>4</Month>
                <Day>10</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11940710</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15752411</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>03</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2005</Year>
            <Month>09</Month>
            <Day>22</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0001-5172</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>49</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Mar</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Acta anaesthesiologica Scandinavica</Title>
                <ISOAbbreviation>Acta Anaesthesiol Scand</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Intensive care treatment of severe mixed metabolic acidosis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>411-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We report a case of severe metabolic acidosis associated with acute renal failure and septicaemia following treatment with maximal therapeutic doses of metformin and diclofenac. On the second day of intensive care the patient deteriorated with respiratory insufficiency and abdominal pain during continuous renal replacement therapy. A laparoscopy revealed a perforated cholecystitis with abscess formation. The patient regained renal function and recovered. Intake of diclofenac 5 days before this episode could have been the main cause of renal insufficiency and metabolic acidosis in this patient and could also have delayed surgical treatment by masking early clinical signs of perforated cholecystitis. The renal failure may also have caused metformin and lactate to accumulate, contributing to the mixed pattern of metabolic acidosis. This case report describes a mixed organic and non-organic metabolic acidosis associated with acute renal failure, presumably resulting from a combination of drugs and diseases often found in the elderly - metformin for diabetes mellitus and a non-steroidal anti-inflammatory drug for cholecystolithiasis. Acid-base balance and electrolyte changes were rapidly normalized by continuous renal replacement therapy.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Schmidt</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Deartment of Anaesthesia and Intensive Care, Lund University, Malmö University Hospital, SE-205 02 Malmö, Sweden. anders.schmidt@skane.se</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Christensson</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Akeson</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Denmark</Country>
            <MedlineTA>Acta Anaesthesiol Scand</MedlineTA>
            <NlmUniqueID>0370270</NlmUniqueID>
            <ISSNLinking>0001-5172</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>144O8QL0L1</RegistryNumber>
                <NameOfSubstance UI="D004008">Diclofenac</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9100L32L2N</RegistryNumber>
                <NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018784">Abdominal Abscess</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000138">Acidosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D058186">Acute Kidney Injury</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001784">Blood Gas Analysis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002764">Cholecystitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000601">surgery</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003924">Diabetes Mellitus, Type 2</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004008">Diclofenac</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007004">Hypoglycemic Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017055">Intensive Care</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010535">Laparoscopy</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008687">Metformin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017582">Renal Replacement Therapy</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000379">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018805">Sepsis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012720">Severity of Illness Index</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2005</Year>
                <Month>9</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>3</Month>
                <Day>9</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">AAS586</ArticleId>
            <ArticleId IdType="doi">10.1111/j.1399-6576.2005.00586.x</ArticleId>
            <ArticleId IdType="pubmed">15752411</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">17505274</PMID>
        <DateCreated>
            <Year>2007</Year>
            <Month>05</Month>
            <Day>16</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2007</Year>
            <Month>06</Month>
            <Day>13</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1535-1815</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>23</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2007</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatric emergency care</Title>
                <ISOAbbreviation>Pediatr Emerg Care</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Acute colchicine intoxication in a child: a case report.</ArticleTitle>
            <Pagination>
                <MedlinePgn>314-7</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Colchicine poisoning is an uncommon, but potentially life-threatening, toxicologic emergency. The clinical features associated with overdose and the options for treatment are discussed. Colchicine poisoning typically shows 3 phases: initially, gastrointestinal symptoms predominate; in the second phase, multiorgan failure may occur, possibly leading to death. If the patient survives, the third phase of recovery follows, during which the patient often presents with hair loss. Early fatality is due to cardiovascular collapse and respiratory failure; however, pancytopenia and overwhelming septicemia can occur later. All patients suspected of having colchicine intoxication because of its unpredictable outcome should be managed according to the principles of intensive care, irrespective of the actual degree of poisoning. In those patients who survive the initial phase of poisoning, filgrastim (granulocyte colony-stimulating factor) offers an effective method of treating pancytopenia and preventing overwhelming septicemia. Daily monitoring of the patients' hematological status is strongly recommended. We are reporting a case of previously healthy girl who developed a multisystem organ failure after colchicine intoxication. The patient recovered completely and had no residual outcome.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Biçer</LastName>
                    <ForeName>Suat</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Pediatric Emergency Department, SSK Bakirköy Maternity and Children Educational Hospital, Istanbul University, Istanbul, Turkey. drsuatb@yahoo.com</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Soysal</LastName>
                    <ForeName>Demet D</ForeName>
                    <Initials>DD</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ctak</LastName>
                    <ForeName>Agop</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uçsel</LastName>
                    <ForeName>Raif</ForeName>
                    <Initials>R</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Karaböcüoğlu</LastName>
                    <ForeName>Metin</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Uzel</LastName>
                    <ForeName>Nedret</ForeName>
                    <Initials>N</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pediatr Emerg Care</MedlineTA>
            <NlmUniqueID>8507560</NlmUniqueID>
            <ISSNLinking>0749-5161</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>3S12J47372</RegistryNumber>
                <NameOfSubstance UI="D004280">Dobutamine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6158TKW0C5</RegistryNumber>
                <NameOfSubstance UI="D010672">Phenytoin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7LXU5N7ZO5</RegistryNumber>
                <NameOfSubstance UI="D005665">Furosemide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>SML2Y3J35T</RegistryNumber>
                <NameOfSubstance UI="D003078">Colchicine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000505">Alopecia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001259">Ataxia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001803">Blood Transfusion</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019090">Case Management</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003078">Colchicine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000506">poisoning</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003131">Combined Modality Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004211">Disseminated Intravascular Coagulation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004280">Dobutamine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005440">Fluid Therapy</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005665">Furosemide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005759">Gastroenteritis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007010">Hyponatremia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007022">Hypotension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009102">Multiple Organ Failure</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010198">Pancytopenia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010672">Phenytoin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011041">Poisoning</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000628">therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2007</Year>
                <Month>6</Month>
                <Day>15</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2007</Year>
                <Month>5</Month>
                <Day>17</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.pec.0000270163.84076.9f</ArticleId>
            <ArticleId IdType="pii">00006565-200705000-00008</ArticleId>
            <ArticleId IdType="pubmed">17505274</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">24705250</PMID>
        <DateCreated>
            <Year>2014</Year>
            <Month>04</Month>
            <Day>28</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>06</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>05</Month>
            <Day>30</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1546-1718</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>46</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2014</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Nature genetics</Title>
                <ISOAbbreviation>Nat. Genet.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>462-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1038/ng.2950</ELocationID>
            <Abstract>
                <AbstractText>Pediatric midline high-grade astrocytomas (mHGAs) are incurable with few treatment targets identified. Most tumors harbor mutations encoding p.Lys27Met in histone H3 variants. In 40 treatment-naive mHGAs, 39 analyzed by whole-exome sequencing, we find additional somatic mutations specific to tumor location. Gain-of-function mutations in ACVR1 occur in tumors of the pons in conjunction with histone H3.1 p.Lys27Met substitution, whereas FGFR1 mutations or fusions occur in thalamic tumors associated with histone H3.3 p.Lys27Met substitution. Hyperactivation of the bone morphogenetic protein (BMP)-ACVR1 developmental pathway in mHGAs harboring ACVR1 mutations led to increased levels of phosphorylated SMAD1, SMAD5 and SMAD8 and upregulation of BMP downstream early-response genes in tumor cells. Global DNA methylation profiles were significantly associated with the p.Lys27Met alteration, regardless of the mutant histone H3 variant and irrespective of tumor location, supporting the role of this substitution in driving the epigenetic phenotype. This work considerably expands the number of potential treatment targets and further justifies pretreatment biopsy in pediatric mHGA as a means to orient therapeutic efforts in this disease.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Fontebasso</LastName>
                    <ForeName>Adam M</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Experimental Medicine, Montreal Children's Hospital, McGill University and McGill University Health Centre, Montreal, Quebec, Canada. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Papillon-Cavanagh</LastName>
                    <ForeName>Simon</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Human Genetics, McGill University, Montreal, Quebec, Canada. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Schwartzentruber</LastName>
                    <ForeName>Jeremy</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Wellcome Trust Sanger Institute, Hinxton, UK. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nikbakht</LastName>
                    <ForeName>Hamid</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gerges</LastName>
                    <ForeName>Noha</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fiset</LastName>
                    <ForeName>Pierre-Olivier</ForeName>
                    <Initials>PO</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bechet</LastName>
                    <ForeName>Denise</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Faury</LastName>
                    <ForeName>Damien</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Human Genetics, McGill University, Montreal, Quebec, Canada. [2] Department of Pediatrics, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>De Jay</LastName>
                    <ForeName>Nicolas</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Human Genetics, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ramkissoon</LastName>
                    <ForeName>Lori A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Corcoran</LastName>
                    <ForeName>Aoife</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jones</LastName>
                    <ForeName>David T W</ForeName>
                    <Initials>DT</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sturm</LastName>
                    <ForeName>Dominik</ForeName>
                    <Initials>D</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Johann</LastName>
                    <ForeName>Pascal</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tomita</LastName>
                    <ForeName>Tadanori</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goldman</LastName>
                    <ForeName>Stewart</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics Hematology-Oncology, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nagib</LastName>
                    <ForeName>Mahmoud</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Pediatric Neurosurgical Oncology, Department of Surgery, Boston Children's Hospital, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bendel</LastName>
                    <ForeName>Anne</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Hematology-Oncology, Children's Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Goumnerova</LastName>
                    <ForeName>Liliana</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Neurosurgery, Boston Children's Hospital, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bowers</LastName>
                    <ForeName>Daniel C</ForeName>
                    <Initials>DC</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leonard</LastName>
                    <ForeName>Jeffrey R</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rubin</LastName>
                    <ForeName>Joshua B</ForeName>
                    <Initials>JB</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Hematology-Oncology, Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Alden</LastName>
                    <ForeName>Tord</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Browd</LastName>
                    <ForeName>Samuel</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Seattle Children's Hospital, Seattle, Washington, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geyer</LastName>
                    <ForeName>J Russell</ForeName>
                    <Initials>JR</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, Washington, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leary</LastName>
                    <ForeName>Sarah</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Cancer and Blood Disorders Center, Seattle Children's Hospital, Seattle, Washington, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jallo</LastName>
                    <ForeName>George</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cohen</LastName>
                    <ForeName>Kenneth</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Hematology-Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gupta</LastName>
                    <ForeName>Nalin</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Prados</LastName>
                    <ForeName>Michael D</ForeName>
                    <Initials>MD</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Carret</LastName>
                    <ForeName>Anne-Sophie</ForeName>
                    <Initials>AS</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Hematology-Oncology, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ellezam</LastName>
                    <ForeName>Benjamin</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Crevier</LastName>
                    <ForeName>Louis</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Université de Montréal, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Klekner</LastName>
                    <ForeName>Almos</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bognar</LastName>
                    <ForeName>Laszlo</ForeName>
                    <Initials>L</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hauser</LastName>
                    <ForeName>Peter</ForeName>
                    <Initials>P</Initials>
                    <AffiliationInfo>
                        <Affiliation>2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Garami</LastName>
                    <ForeName>Miklos</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>2nd Department of Paediatrics, Semmelweis University, Budapest, Hungary.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Myseros</LastName>
                    <ForeName>John</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurosurgery, Children's National Medical Center, Washington, DC, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dong</LastName>
                    <ForeName>Zhifeng</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Siegel</LastName>
                    <ForeName>Peter M</ForeName>
                    <Initials>PM</Initials>
                    <Identifier Source="ORCID">0000000255686586</Identifier>
                    <AffiliationInfo>
                        <Affiliation>Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Malkin</LastName>
                    <ForeName>Hayley</ForeName>
                    <Initials>H</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ligon</LastName>
                    <ForeName>Azra H</ForeName>
                    <Initials>AH</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Albrecht</LastName>
                    <ForeName>Steffen</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pathology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Pfister</LastName>
                    <ForeName>Stefan M</ForeName>
                    <Initials>SM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ligon</LastName>
                    <ForeName>Keith L</ForeName>
                    <Initials>KL</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Medical Oncology, Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [2] Harvard Medical School, Boston, Massachusetts, USA. [3] Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA. [4] Department of Pathology, Boston Children's Hospital, Boston, Massachusetts, USA. [5].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Majewski</LastName>
                    <ForeName>Jacek</ForeName>
                    <Initials>J</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Department of Human Genetics, McGill University, Montreal, Quebec, Canada. [2].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Jabado</LastName>
                    <ForeName>Nada</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Division of Experimental Medicine, Montreal Children's Hospital, McGill University and McGill University Health Centre, Montreal, Quebec, Canada. [2] Department of Human Genetics, McGill University, Montreal, Quebec, Canada. [3] Department of Pediatrics, McGill University, Montreal, Quebec, Canada. [4].</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kieran</LastName>
                    <ForeName>Mark W</ForeName>
                    <Initials>MW</Initials>
                    <AffiliationInfo>
                        <Affiliation>1] Harvard Medical School, Boston, Massachusetts, USA. [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. [3] Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts, USA. [4].</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <DataBankList CompleteYN="Y">
                <DataBank>
                    <DataBankName>GEO</DataBankName>
                    <AccessionNumberList>
                        <AccessionNumber>GSE55712</AccessionNumber>
                    </AccessionNumberList>
                </DataBank>
            </DataBankList>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>P01 CA142536</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <GrantID>P30 CA060553</GrantID>
                    <Acronym>CA</Acronym>
                    <Agency>NCI NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
                <Grant>
                    <Agency>Canadian Institutes of Health Research</Agency>
                    <Country>Canada</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2014</Year>
                <Month>04</Month>
                <Day>06</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Nat Genet</MedlineTA>
            <NlmUniqueID>9216904</NlmUniqueID>
            <ISSNLinking>1061-4036</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D019485">Bone Morphogenetic Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051785">Smad Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="C425423">ACVR1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.30</RegistryNumber>
                <NameOfSubstance UI="D030201">Activin Receptors, Type I</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Res. 2010 Sep;20(9):1297-303</RefSource>
                <PMID Version="1">20644199</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2010 Jun 20;28(18):3061-8</RefSource>
                <PMID Version="1">20479398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2011 Oct 20;29(30):3999-4006</RefSource>
                <PMID Version="1">21931021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS Comput Biol. 2011 May;7(5):e1001138</RefSource>
                <PMID Version="1">21625565</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2011 Mar 15;108(11):4453-8</RefSource>
                <PMID Version="1">21368213</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Development. 2012 Mar;139(5):894-905</RefSource>
                <PMID Version="1">22278924</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2012 Feb 9;482(7384):226-31</RefSource>
                <PMID Version="1">22286061</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2012 Mar;44(3):251-3</RefSource>
                <PMID Version="1">22286216</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Neuropathol. 2012 Sep;124(3):439-47</RefSource>
                <PMID Version="1">22661320</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2012 Sep 7;337(6099):1231-5</RefSource>
                <PMID Version="1">22837387</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genome Biol. 2012;13(6):R44</RefSource>
                <PMID Version="1">22703947</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer Cell. 2012 Oct 16;22(4):425-37</RefSource>
                <PMID Version="1">23079654</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2012 Oct 26;287(44):36990-8</RefSource>
                <PMID Version="1">22977237</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2013 Feb 22;339(6122):959-61</RefSource>
                <PMID Version="1">23348503</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Neuropathol. 2013 May;125(5):659-69</RefSource>
                <PMID Version="1">23417712</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2013 May 14;110(20):8188-93</RefSource>
                <PMID Version="1">23633565</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2013 May 17;340(6134):857-61</RefSource>
                <PMID Version="1">23539183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Jun;45(6):602-12</RefSource>
                <PMID Version="1">23583981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2013 Aug;45(8):927-32</RefSource>
                <PMID Version="1">23817572</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2014 Jan;46(1):39-44</RefSource>
                <PMID Version="1">24316981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nucleic Acids Res. 2010 Sep;38(16):e164</RefSource>
                <PMID Version="1">20601685</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Oncol. 2010 Mar 10;28(8):1337-44</RefSource>
                <PMID Version="1">20142589</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2002 Feb 15;277(7):4883-91</RefSource>
                <PMID Version="1">11729207</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EMBO J. 1999 Apr 15;18(8):2149-64</RefSource>
                <PMID Version="1">10205169</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Biol. 1999 Sep 15;213(2):314-26</RefSource>
                <PMID Version="1">10479450</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Biol. 2004 Dec 1;276(1):185-93</RefSource>
                <PMID Version="1">15531373</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cytokine Growth Factor Rev. 2005 Jun;16(3):251-63</RefSource>
                <PMID Version="1">15871923</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Genesis. 2006 Apr;44(4):159-67</RefSource>
                <PMID Version="1">16604518</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Genet. 2006 May;38(5):525-7</RefSource>
                <PMID Version="1">16642017</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2006 Jun 15;22(12):1540-2</RefSource>
                <PMID Version="1">16595560</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2007 Dec;8(12):970-82</RefSource>
                <PMID Version="1">18000526</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nature. 2008 Sep 25;455(7212):547-51</RefSource>
                <PMID Version="1">18794900</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem Biophys Res Commun. 2008 Dec 19;377(3):905-9</RefSource>
                <PMID Version="1">18952055</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Jul 15;25(14):1754-60</RefSource>
                <PMID Version="1">19451168</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Bioinformatics. 2009 Aug 15;25(16):2078-9</RefSource>
                <PMID Version="1">19505943</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Invest. 2009 Nov;119(11):3462-72</RefSource>
                <PMID Version="1">19855136</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Genet. 2014 May;46(5):421-2</RefSource>
                <PMID Version="1">24769718</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Nat Rev Clin Oncol. 2014 Jun;11(6):300</RefSource>
                <PMID Version="1">24840074</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D030201">Activin Receptors, Type I</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001254">Astrocytoma</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001483">Base Sequence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019485">Bone Morphogenetic Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001932">Brain Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056915">DNA Copy Number Variations</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019175">DNA Methylation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015972">Gene Expression Regulation, Neoplastic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015894">Genome, Human</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007150">Immunohistochemistry</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017404">In Situ Hybridization, Fluorescence</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008969">Molecular Sequence Data</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009154">Mutation</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017422">Sequence Analysis, DNA</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051785">Smad Proteins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">NIHMS650089</OtherID>
        <OtherID Source="NLM">PMC4282994</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>10</Month>
                <Day>03</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2014</Year>
                <Month>3</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>06</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2014</Year>
                <Month>4</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>6</Month>
                <Day>17</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">ng.2950</ArticleId>
            <ArticleId IdType="doi">10.1038/ng.2950</ArticleId>
            <ArticleId IdType="pubmed">24705250</ArticleId>
            <ArticleId IdType="pmc">PMC4282994</ArticleId>
            <ArticleId IdType="mid">NIHMS650089</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16340173</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>12</Month>
            <Day>12</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>01</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0040-8727</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>208</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Jan</Month>
                    </PubDate>
                </JournalIssue>
                <Title>The Tohoku journal of experimental medicine</Title>
                <ISOAbbreviation>Tohoku J. Exp. Med.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Lack of an association between a newly identified promoter polymorphism (-1702G &gt; A) of the leukotriene C4 synthase gene and aspirin-intolerant asthma in a Korean population.</ArticleTitle>
            <Pagination>
                <MedlinePgn>49-56</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Aspirin-intolerant asthma (AIA) is a distinct clinical syndrome that refers to the development of bronchoconstriction in asthmatic individuals following the ingestion of aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs). It is widely recognized that increased cysteinyl leukotriene (cysLT) biosynthesis is associated with the development and progression of AIA. Leukotriene C4 synthase (LTC4S) is the terminal enzyme in cysLT production and is a strong candidate gene in the pathogenesis of aspirin-intolerant asthma (AIA). In this paper, we report a new single nucleotide polymorphism (SNP) of the LTC4S promoter, -1702G&gt;A, in AIA patients and evaluate its genetic role in the association with the LTC4S-444 A&gt;C polymorphism. We enrolled 110 AIA patients, 125 aspirin-tolerant asthma (ATA) patients, and 125 normal controls. SNP genotyping of the LTC4S-1702G&gt;A and -444A&gt;C polymorphisms was performed using SNP-IT assays. Haplotype analyses were performed using Haploview version 2.05, which is based on an estimation-maximization (EM) algorithm. There were no significant differences in the allele or genotype frequencies of the LTC4S-1702G&gt;A and -444A&gt;C polymorphisms among the three groups (p &gt; 0.05), with no significant differences in the observed haplotype frequencies (p &gt; 0.05). Moreover, no significant associations were found between the genotype of each SNP in AIA patients with the clinical characteristics, including a forced expiratory volume in one second (FEV1) %, a provocation concentration of methacholine to induce more than 20% decrease of FEV1 (PC20) to methacholine, and serum total IgE levels (p &gt; 0.05). These results indicate that there is no association between these two promoter polymorphisms of LTC4S and the phenotype of AIA in a Korean population.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Choi</LastName>
                    <ForeName>Jeong-Hee</ForeName>
                    <Initials>JH</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pulmonology and Allergies, Bundang Jesaeng General Hospital, Seongnam, Korea.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kim</LastName>
                    <ForeName>Seung-Hyun</ForeName>
                    <Initials>SH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bae</LastName>
                    <ForeName>Jin-Sik</ForeName>
                    <Initials>JS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yu</LastName>
                    <ForeName>Hong-Lei</ForeName>
                    <Initials>HL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Suh</LastName>
                    <ForeName>Chang-Hee</ForeName>
                    <Initials>CH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Nahm</LastName>
                    <ForeName>Dong-Ho</ForeName>
                    <Initials>DH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Park</LastName>
                    <ForeName>Hae-Sim</ForeName>
                    <Initials>HS</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Japan</Country>
            <MedlineTA>Tohoku J Exp Med</MedlineTA>
            <NlmUniqueID>0417355</NlmUniqueID>
            <ISSNLinking>0040-8727</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>EC 2.5.1.18</RegistryNumber>
                <NameOfSubstance UI="D005982">Glutathione Transferase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 4.4.1.20</RegistryNumber>
                <NameOfSubstance UI="C041116">leukotriene-C4 synthase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>R16CO5Y76E</RegistryNumber>
                <NameOfSubstance UI="D001241">Aspirin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D001241">Aspirin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000276">immunology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D001249">Asthma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005982">Glutathione Transferase</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" Type="Geographic" UI="D007723">Korea</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D020641">Polymorphism, Single Nucleotide</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D011401">Promoter Regions, Genetic</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>12</Month>
                <Day>13</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">JST.JSTAGE/tjem/208.49</ArticleId>
            <ArticleId IdType="pubmed">16340173</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">2589455</PMID>
        <DateCreated>
            <Year>1990</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1990</Year>
            <Month>01</Month>
            <Day>04</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0002-9378</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>161</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>1989</Year>
                        <Month>Nov</Month>
                    </PubDate>
                </JournalIssue>
                <Title>American journal of obstetrics and gynecology</Title>
                <ISOAbbreviation>Am. J. Obstet. Gynecol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Clinical experience with phenytoin prophylaxis in severe preeclampsia.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1297-304</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>In North America, magnesium sulfate is the traditional treatment for severe preeclampsia and eclampsia. Its use has been strongly criticized, in that it acts peripherally with no central effect and maternal and neonatal complications are well known. Phenytoin, the mechanism of action of which is clear, seems a logical alternative. Our aim was to develop a safe, practical, effective regimen with the use of phenytoin. In this prospective, descriptive study four dosage regimens were investigated in 104 patients. The initial regimens produced unexpected and unacceptable side effects in comparison with the nonpregnant population. The final regimen (15 mg/kg intravenously, given as 10 mg/kg initially then 5 mg/kg 2 hours later) provided therapeutic levels and had minimal maternal and perinatal side effects. No seizures occurred after its correct usage. This regimen is simple, safe, effective, and provides ongoing anticonvulsant coverage in the postpartum period. We suggest that phenytoin may represent a suitable alternative anticonvulsant in this condition.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ryan</LastName>
                    <ForeName>G</ForeName>
                    <Initials>G</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Obstetrics and Gynaecology, St. Boniface General Hospital, University of Manitoba, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lange</LastName>
                    <ForeName>I R</ForeName>
                    <Initials>IR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Naugler</LastName>
                    <ForeName>M A</ForeName>
                    <Initials>MA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Am J Obstet Gynecol</MedlineTA>
            <NlmUniqueID>0370476</NlmUniqueID>
            <ISSNLinking>0002-9378</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>6158TKW0C5</RegistryNumber>
                <NameOfSubstance UI="D010672">Phenytoin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="CommentIn">
                <RefSource>Am J Obstet Gynecol. 1990 Sep;163(3):1089-91</RefSource>
                <PMID Version="1">2403135</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001264">Athetosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002585">Cesarean Section</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002819">Chorea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D036861">Delivery, Obstetric</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004334">Drug Administration Schedule</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007022">Hypotension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010672">Phenytoin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011225">Pre-Eclampsia</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011247">Pregnancy</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1989</Year>
                <Month>11</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1989</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1989</Year>
                <Month>11</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">2589455</ArticleId>
            <ArticleId IdType="pii">0002-9378(89)90687-X</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12165618</PMID>
        <DateCreated>
            <Year>2002</Year>
            <Month>08</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>09</Month>
            <Day>16</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1098-4275</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>110</Volume>
                    <Issue>2 Pt 1</Issue>
                    <PubDate>
                        <Year>2002</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Pediatrics</Title>
                <ISOAbbreviation>Pediatrics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e19</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Prolonged administration of indinavir is associated with the occurrence of a variety of renal complications in adults. These well-documented side effects have restricted the use of this potent protease inhibitor in children.</AbstractText>
                <AbstractText Label="DESIGN" NlmCategory="METHODS">A prospective study to monitor indinavir-related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1-infected children treated with indinavir.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Urinary pH, albumin, creatinine, the presence of erythrocytes, leukocytes, bacteria and crystals, and culture were analyzed every 3 months for 96 weeks. Serum creatinine levels were routinely determined at the same time points. Steady-state pharmacokinetics of indinavir were done at week 4 after the initiation of indinavir.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The cumulative incidence of persistent sterile leukocyturia (&gt; or =75 cells/ micro L in at least 2 consecutive visits) after 96 weeks was 53%. Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin/creatinine ratio and by microscopic hematuria. The cumulative incidence of serum creatinine levels &gt;50% above normal was 33% after 96 weeks. Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50% above normal than those children without persistent sterile leukocyturia. In children younger than 5.6 years, persistent sterile leukocyturia was significantly more frequent than in older children. A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve &gt;19 mg/L x h or a peak serum level of indinavir &gt;12 mg/L. In 4 children, indinavir was discontinued because of nephrotoxicity. Subsequently, the serum creatinine levels decreased, the urine albumin/creatinine ratios returned to zero, and the leukocyturia disappeared within 3 months.</AbstractText>
                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia. Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of &gt;50% above normal. Younger children have an additional risk for renal complications. The impairment of the renal function in these children occurred in the absence of clinical symptoms of nephrolithiasis. Indinavir-associated nephrotoxicity must be monitored closely, especially in children with risk factors such as persistent sterile leukocyturia, age &lt;5.6 years, an area under the curve of indinavir &gt;19 mg/L x h, and a C(max) &gt;12 mg/L.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>van Rossum</LastName>
                    <ForeName>Annemarie M C</ForeName>
                    <Initials>AM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Pediatrics, Sophia Children's Hospital/Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Dieleman</LastName>
                    <ForeName>Jeanne P</ForeName>
                    <Initials>JP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fraaij</LastName>
                    <ForeName>Pieter L A</ForeName>
                    <Initials>PL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cransberg</LastName>
                    <ForeName>Karlien</ForeName>
                    <Initials>K</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Hartwig</LastName>
                    <ForeName>Nico G</ForeName>
                    <Initials>NG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burger</LastName>
                    <ForeName>David M</ForeName>
                    <Initials>DM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gyssens</LastName>
                    <ForeName>Inge C</ForeName>
                    <Initials>IC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>de Groot</LastName>
                    <ForeName>Ronald</ForeName>
                    <Initials>R</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Pediatrics</MedlineTA>
            <NlmUniqueID>0376422</NlmUniqueID>
            <ISSNLinking>0031-4005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>5W6YA9PKKH</RegistryNumber>
                <NameOfSubstance UI="D019469">Indinavir</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AYI8EX34EU</RegistryNumber>
                <NameOfSubstance UI="D003404">Creatinine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002648">Child</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002675">Child, Preschool</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003404">Creatinine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000097">blood</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015658">HIV Infections</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017320">HIV Protease Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019469">Indinavir</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007674">Kidney Diseases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000175">diagnosis</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007964">Leukocytosis</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000652">urine</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011446">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D016482">Urinalysis</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>9</Month>
                <Day>17</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2002</Year>
                <Month>8</Month>
                <Day>8</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12165618</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11699532</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>11</Month>
            <Day>08</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2002</Year>
            <Month>03</Month>
            <Day>20</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1045-3873</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>12</Volume>
                    <Issue>10</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Oct</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cardiovascular electrophysiology</Title>
                <ISOAbbreviation>J. Cardiovasc. Electrophysiol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Asymptomatic brugada syndrome case unmasked during dimenhydrinate infusion.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1192-4</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Typical ECG of that described for Brugada syndrome was elicited in a patient diagnosed with labyrinthopathy during infusion of dimenhydrinate, a first-generation antihistamine usually used to treat motion sickness. Although the patient had no history of syncope or palpitations, and there was no family history of cardiac disease or sudden death, the ECG abnormality was reproduced later with intravenous flecainide, and an asymptomatic Brugada syndrome was diagnosed.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Pastor</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Clinical Electrophysiology Laboratory, Cardiology Service, Hospital Universitario de Getafe, Madrid, Spain. apastor@hugf.insalud.es</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Núñez</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cantale</LastName>
                    <ForeName>C</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cosío</LastName>
                    <ForeName>F G</ForeName>
                    <Initials>FG</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Cardiovasc Electrophysiol</MedlineTA>
            <NlmUniqueID>9010756</NlmUniqueID>
            <ISSNLinking>1045-3873</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006634">Histamine H1 Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>JB937PER5C</RegistryNumber>
                <NameOfSubstance UI="D004111">Dimenhydrinate</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002037">Bundle-Branch Block</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004111">Dimenhydrinate</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004562">Electrocardiography</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006634">Histamine H1 Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D007260">Infusion Pumps</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013577">Syndrome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017180">Tachycardia, Ventricular</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000175">diagnosis</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2002</Year>
                <Month>3</Month>
                <Day>21</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>11</Month>
                <Day>9</Day>
                <Hour>10</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11699532</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">8630861</PMID>
        <DateCreated>
            <Year>1996</Year>
            <Month>07</Month>
            <Day>01</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1996</Year>
            <Month>07</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0008-543X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>76</Volume>
                    <Issue>1</Issue>
                    <PubDate>
                        <Year>1995</Year>
                        <Month>Jul</Month>
                        <Day>1</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Cancer</Title>
                <ISOAbbreviation>Cancer</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Docetaxel (Taxotere) associated scleroderma-like changes of the lower extremities. A report of three cases.</ArticleTitle>
            <Pagination>
                <MedlinePgn>110-5</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Docetaxel (Taxotere) is a microtubule-stabilizing agent that is potentially important in chemotherapy for a variety of malignancies.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">A clinical study of the cutaneous reactions experienced by a group of patients receiving docetaxel chemotherapy was undertaken. Patients were examined before initiation of therapy, before and after each cycle of therapy, and were followed subsequent to the completion of docetaxel chemotherapy.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Three patients developed diffuse lower extremity edema (3-18 kg) and subsequent scleroderma-like changes after receiving multiple cycles of docetaxel therapy. These patients had different underlying malignancies and dissimilar prior therapy. Rheumatoid factor, antinuclear antibodies, anticentromere, and topoisomerase antibodies were not present in any patient. The diffuse lower extremity edema did not resolve with diuretic therapy. Cutaneous biopsies in two patients revealed diffuse sclerosis. One patient had a normal lymphangiogram during the edematous phase. Discontinuation of docetaxel correlated with resolution of edema and softening of the skin.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The etiology of the scleroderma-like skin changes is unclear but appears to be either a toxic effect of docetaxel or an effect of polysorbate 80 (Tween 80), the vehicle for docetaxel.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Battafarano</LastName>
                    <ForeName>D F</ForeName>
                    <Initials>DF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Brooke Army Medical Center, San Antonio, Texas 78234, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zimmerman</LastName>
                    <ForeName>G C</ForeName>
                    <Initials>GC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Older</LastName>
                    <ForeName>S A</ForeName>
                    <Initials>SA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Keeling</LastName>
                    <ForeName>J H</ForeName>
                    <Initials>JH</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Burris</LastName>
                    <ForeName>H A</ForeName>
                    <Initials>HA</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Cancer</MedlineTA>
            <NlmUniqueID>0374236</NlmUniqueID>
            <ISSNLinking>0008-543X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000972">Antineoplastic Agents, Phytogenic</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>15H5577CQD</RegistryNumber>
                <NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33069-62-4</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>AIM</CitationSubset>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000368">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000505">Alopecia</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000972">Antineoplastic Agents, Phytogenic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004487">Edema</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007866">Leg</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007890">Leiomyosarcoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008175">Lung Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008545">Melanoma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012594">Scleroderma, Localized</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D043823">Taxoids</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1995</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1995</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1995</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">8630861</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">21652713</PMID>
        <DateCreated>
            <Year>2011</Year>
            <Month>07</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2011</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>10</Month>
            <Day>22</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1083-351X</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>286</Volume>
                    <Issue>30</Issue>
                    <PubDate>
                        <Year>2011</Year>
                        <Month>Jul</Month>
                        <Day>29</Day>
                    </PubDate>
                </JournalIssue>
                <Title>The Journal of biological chemistry</Title>
                <ISOAbbreviation>J. Biol. Chem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inositol hexakisphosphate kinases induce cell death in Huntington disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>26680-6</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1074/jbc.M111.220749</ELocationID>
            <Abstract>
                <AbstractText>Inositol pyrophosphate diphosphoinositol pentakisphosphate is ubiquitously present in mammalian cells and contains highly energetic pyrophosphate bonds. We have previously reported that inositol hexakisphosphate kinase type 2 (InsP(6)K2), which converts inositol hexakisphosphate to inositol pyrophosphate diphosphoinositol pentakisphosphate, mediates apoptotic cell death via its translocation from the nucleus to the cytoplasm. Here, we report that InsP(6)K2 is localized mainly in the cytoplasm of lymphoblast cells from patients with Huntington disease (HD), whereas this enzyme is localized in the nucleus in control lymphoblast cells. The large number of autophagosomes detected in HD lymphoblast cells is consistent with the down-regulation of Akt in response to InsP(6)K2 activation. Consistent with these observations, the overexpression of InsP(6)Ks leads to the depletion of Akt phosphorylation and the induction of cell death. These results suggest that InsP(6)K2 activation is associated with the pathogenesis of HD.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Nagata</LastName>
                    <ForeName>Eiichiro</ForeName>
                    <Initials>E</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Neurology, Tokai University School of Medicine, Kanagawa 259-1193, Japan. enagata@is.icc.u-tokai.ac.jp</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Saiardi</LastName>
                    <ForeName>Adolfo</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tsukamoto</LastName>
                    <ForeName>Hideo</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Okada</LastName>
                    <ForeName>Yoshinori</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itoh</LastName>
                    <ForeName>Yoshiko</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Satoh</LastName>
                    <ForeName>Tadayuki</ForeName>
                    <Initials>T</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Itoh</LastName>
                    <ForeName>Johbu</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Margolis</LastName>
                    <ForeName>Russell L</ForeName>
                    <Initials>RL</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takizawa</LastName>
                    <ForeName>Shunya</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sawa</LastName>
                    <ForeName>Akira</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Takagi</LastName>
                    <ForeName>Shigeharu</ForeName>
                    <Initials>S</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>MC_U122680443</GrantID>
                    <Agency>Medical Research Council</Agency>
                    <Country>United Kingdom</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2011</Year>
                <Month>06</Month>
                <Day>07</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Biol Chem</MedlineTA>
            <NlmUniqueID>2985121R</NlmUniqueID>
            <ISSNLinking>0021-9258</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>7IGF0S7R8I</RegistryNumber>
                <NameOfSubstance UI="D010833">Phytic Acid</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.11.1</RegistryNumber>
                <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.4.-</RegistryNumber>
                <NameOfSubstance UI="D017856">Phosphotransferases (Phosphate Group Acceptor)</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 2.7.4.21</RegistryNumber>
                <NameOfSubstance UI="C115134">IP6K1 protein, human</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2000 Oct 13;103(2):253-62</RefSource>
                <PMID Version="1">11057898</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2010 Dec 10;143(6):897-910</RefSource>
                <PMID Version="1">21145457</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Oncogene. 2002 Mar 14;21(12):1882-9</RefSource>
                <PMID Version="1">11896621</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Dev Cell. 2002 Jun;2(6):831-7</RefSource>
                <PMID Version="1">12062094</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14206-11</RefSource>
                <PMID Version="1">12391334</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>EMBO Rep. 2002 Dec;3(12):1139-45</RefSource>
                <PMID Version="1">12475927</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell. 2003 Sep 5;114(5):559-72</RefSource>
                <PMID Version="1">13678580</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroreport. 2004 Jun 7;15(8):1325-8</RefSource>
                <PMID Version="1">15167559</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biochem J. 1993 Jul 15;293 ( Pt 2):583-90</RefSource>
                <PMID Version="1">8343137</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Semin Cell Biol. 1994 Aug;5(4):273-81</RefSource>
                <PMID Version="1">7994011</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4305-10</RefSource>
                <PMID Version="1">8633060</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Pathol Int. 1996 Oct;46(10):726-37</RefSource>
                <PMID Version="1">8916141</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Med. 1999 Oct;5(10):1194-8</RefSource>
                <PMID Version="1">10502825</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2005 Jan 14;280(2):1634-40</RefSource>
                <PMID Version="1">15533939</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):1911-4</RefSource>
                <PMID Version="1">15665079</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Neurosci. 2005 Mar;21(6):1478-88</RefSource>
                <PMID Version="1">15845076</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Mol Life Sci. 2006 Mar;63(5):552-64</RefSource>
                <PMID Version="1">16429326</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Protoc. 2006;1(5):2416-22</RefSource>
                <PMID Version="1">17406485</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Neurochem. 2007 Sep;102(5):1426-46</RefSource>
                <PMID Version="1">17697045</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Science. 2007 Nov 23;318(5854):1299-302</RefSource>
                <PMID Version="1">18033884</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2349-53</RefSource>
                <PMID Version="1">18268345</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>FEBS J. 2008 Sep;275(17):4263-70</RefSource>
                <PMID Version="1">18637946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Rev Mol Cell Biol. 2008 Dec;9(12):1004-10</RefSource>
                <PMID Version="1">18971948</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biochem Cell Biol. 2009 May;41(5):1006-10</RefSource>
                <PMID Version="1">18992839</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2009;4(5):e5580</RefSource>
                <PMID Version="1">19440344</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2010;5(4):e9979</RefSource>
                <PMID Version="1">20376313</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2010 Apr 23;285(17):13107-20</RefSource>
                <PMID Version="1">20178983</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Nat Neurosci. 2010 May;13(5):567-76</RefSource>
                <PMID Version="1">20383138</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mol Genet. 2010 Oct 1;19(19):3702-20</RefSource>
                <PMID Version="1">20616151</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>PLoS One. 2010;5(9). pii: e12845. doi: 10.1371/journal.pone.0012845</RefSource>
                <PMID Version="1">20862226</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Int J Biochem Cell Biol. 2010 Dec;42(12):2065-71</RefSource>
                <PMID Version="1">20883817</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2001 Oct 19;276(42):39179-85</RefSource>
                <PMID Version="1">11502751</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D017209">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002467">Cell Nucleus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003593">Cytoplasm</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004789">Enzyme Activation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D057809">HEK293 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006816">Huntington Disease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008214">Lymphocytes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000648">ultrastructure</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010766">Phosphorylation</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017856">Phosphotransferases (Phosphate Group Acceptor)</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010833">Phytic Acid</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051057">Proto-Oncogene Proteins c-akt</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3143631</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>7</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2011</Year>
                <Month>6</Month>
                <Day>10</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2011</Year>
                <Month>9</Month>
                <Day>29</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">M111.220749</ArticleId>
            <ArticleId IdType="doi">10.1074/jbc.M111.220749</ArticleId>
            <ArticleId IdType="pubmed">21652713</ArticleId>
            <ArticleId IdType="pmc">PMC3143631</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">6196650</PMID>
        <DateCreated>
            <Year>1984</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1984</Year>
            <Month>01</Month>
            <Day>07</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0275-1380</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>5</Volume>
                    <Issue>4</Issue>
                    <PubDate>
                        <MedlineDate>1983 Jul-Aug</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Neurobehavioral toxicology and teratology</Title>
                <ISOAbbreviation>Neurobehav Toxicol Teratol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Proconvulsant action of lindane compared at two different kindling sites in the rat--amygdala and hippocampus.</ArticleTitle>
            <Pagination>
                <MedlinePgn>465-8</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Lindane facilitates the rate of acquisition of a maximal kindled amygdaloid response (MKAR) in rats. We tested whether this is a site specific effect or a more generalized one by comparing acquisition of MKAR and of the maximal kindled hippocampal response (MKHR). The hippocampus was chosen for comparison because acquisition of MKHR requires 2-3 times more trials than does acquisition of MKAR. Rats were implanted with electrodes in amygdala or hippocampus and exposed to either 0 or 5 mg/kg/day lindane, orally, throughout the acquisition period. Lindane exposure reduced the number of trials needed to acquire MKAR and MKHR to the same extent, 70 +/- 5 and 69 +/- 11% of control rats, respectively. However, the specifics of the facilitation varied between sites. The facilitation of amygdaloid kindling acquisition was associated with an increase in the length of afterdischarge (AD) produced on each trial. The cumulative seconds of AD (CSAD) accrued by amygdaloid rats given lindane was the same (95 +/- 15%) as control rats. During hippocampal kindling lindane exposure reduced AD durations. The facilitation of hippocampal kindling was associated with a reduction in total AD experience. Hippocampal rats given lindane accrued only 52 +/- 7% of the CSAD accrued by control rats.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Joy</LastName>
                    <ForeName>R M</ForeName>
                    <Initials>RM</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Stark</LastName>
                    <ForeName>L G</ForeName>
                    <Initials>LG</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Albertson</LastName>
                    <ForeName>T E</ForeName>
                    <Initials>TE</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <GrantList CompleteYN="Y">
                <Grant>
                    <GrantID>2S07RR05457</GrantID>
                    <Acronym>RR</Acronym>
                    <Agency>NCRR NIH HHS</Agency>
                    <Country>United States</Country>
                </Grant>
            </GrantList>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
                <PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Neurobehav Toxicol Teratol</MedlineTA>
            <NlmUniqueID>8104162</NlmUniqueID>
            <ISSNLinking>0275-1380</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>59NEE7PCAB</RegistryNumber>
                <NameOfSubstance UI="D001556">Lindane</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000679">Amygdala</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005071">Evoked Potentials</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006624">Hippocampus</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007696">Kindling, Neurologic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001556">Lindane</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011919">Rats, Inbred Strains</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012640">Seizures</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1983</Year>
                <Month>7</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1983</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1983</Year>
                <Month>7</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">6196650</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">15933791</PMID>
        <DateCreated>
            <Year>2005</Year>
            <Month>06</Month>
            <Day>03</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2006</Year>
            <Month>01</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Print">0100-879X</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>38</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2005</Year>
                        <Month>Jun</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica ... [et al.]</Title>
                <ISOAbbreviation>Braz. J. Med. Biol. Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Acetylcholine and bradykinin enhance hypotension and affect the function of remodeled conduit arteries in SHR and SHR treated with nitric oxide donors.</ArticleTitle>
            <Pagination>
                <MedlinePgn>959-66</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>Discrepancy was found between enhanced hypotension and attenuated relaxation of conduit arteries in response to acetylcholine (ACh) and bradykinin (BK) in nitric oxide (NO)-deficient hypertension. The question is whether a similar phenomenon occurs in spontaneously hypertensive rats (SHR) with a different pathogenesis. Wistar rats, SHR, and SHR treated with NO donors [molsidomine (50 mg/kg) or pentaerythritol tetranitrate (100 mg/kg), twice a day, by gavage] were studied. After 6 weeks of treatment systolic blood pressure (BP) was increased significantly in experimental groups. Under anesthesia, the carotid artery was cannulated for BP recording and the jugular vein for drug administration. The iliac artery was used for in vitro studies and determination of geometry. Compared to control, SHR showed a significantly enhanced (P &lt; 0.01) hypotensive response to ACh (1 and 10 microg, 87.9 +/- 6.9 and 108.1 +/- 5.1 vs 35.9 +/- 4.7 and 64.0 +/- 3.3 mmHg), and BK (100 microg, 106.7 +/- 8.3 vs 53.3 +/- 5.2 mmHg). SHR receiving NO donors yielded similar results. In contrast, maximum relaxation of the iliac artery in response to ACh was attenuated in SHR (12.1 +/- 3.6 vs 74.2 +/- 8.6% in controls, P &lt; 0.01). Iliac artery inner diameter also increased (680 +/- 46 vs 828 +/- 28 microm in controls, P &lt; 0.01). Wall thickness, wall cross-section area, wall thickness/inner diameter ratio increased significantly (P &lt; 0.01). No differences were found in this respect among SHR and SHR treated with NO donors. These findings demonstrated enhanced hypotension and attenuated relaxation of the conduit artery in response to NO activators in SHR and in SHR treated with NO donors, a response similar to that found in NO-deficient hypertension.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gerová</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                    <AffiliationInfo>
                        <Affiliation>Institute of Normal and Pathological Physiology, Academy of Sciences, 813 71 Bratislava, Slovakia. maria.gerova@savba.sk</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kristek</LastName>
                    <ForeName>F</ForeName>
                    <Initials>F</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cacányiová</LastName>
                    <ForeName>S</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cebová</LastName>
                    <ForeName>M</ForeName>
                    <Initials>M</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2005</Year>
                <Month>06</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Brazil</Country>
            <MedlineTA>Braz J Med Biol Res</MedlineTA>
            <NlmUniqueID>8112917</NlmUniqueID>
            <ISSNLinking>0100-879X</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020030">Nitric Oxide Donors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>10L39TRG1Z</RegistryNumber>
                <NameOfSubstance UI="D010417">Pentaerythritol Tetranitrate</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>D46583G77X</RegistryNumber>
                <NameOfSubstance UI="D008981">Molsidomine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.13.39</RegistryNumber>
                <NameOfSubstance UI="D019001">Nitric Oxide Synthase</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N9YNS0M02X</RegistryNumber>
                <NameOfSubstance UI="D000109">Acetylcholine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>S8TIM42R2W</RegistryNumber>
                <NameOfSubstance UI="D001920">Bradykinin</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000109">Acetylcholine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001794">Blood Pressure</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001920">Bradykinin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002339">Carotid Arteries</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007022">Hypotension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007083">Iliac Artery</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000502">physiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008981">Molsidomine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020030">Nitric Oxide Donors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019001">Nitric Oxide Synthase</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010417">Pentaerythritol Tetranitrate</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011918">Rats, Inbred SHR</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014665">Vasodilator Agents</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="aheadofprint">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2006</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2005</Year>
                <Month>6</Month>
                <Day>4</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0100-879X2005000600019</ArticleId>
            <ArticleId IdType="doi">/S0100-879X2005000600019</ArticleId>
            <ArticleId IdType="pubmed">15933791</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">16628357</PMID>
        <DateCreated>
            <Year>2006</Year>
            <Month>04</Month>
            <Day>21</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2013</Year>
            <Month>12</Month>
            <Day>19</Day>
        </DateCompleted>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0371-0874</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>58</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2006</Year>
                        <Month>Apr</Month>
                        <Day>25</Day>
                    </PubDate>
                </JournalIssue>
                <Title>Sheng li xue bao : [Acta physiologica Sinica]</Title>
                <ISOAbbreviation>Sheng Li Xue Bao</ISOAbbreviation>
            </Journal>
            <ArticleTitle>[Simvastatin inhibits hypertension-induced cardiac hypertrophy in rats through activation of heme oxygenase-1/carbon monoxide pathway].</ArticleTitle>
            <Pagination>
                <MedlinePgn>116-23</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>To investigate the anti-cardiac hypertrophic mechanism of statins, thirty-eight male Wistar rats were randomly allocated to four groups. Rats in model group received nitric oxide synthase inhibitor, N-nitro-L-arginine (L-NNA) 15 mg/(kg.d) by peritoneal injection. Rats in simvastatin treatment groups were given simultaneously L-NNA as those in model group and simvastatin 5 or 30 mg/(kg.d) intragastrically respectively. Rats in control group received the same volume of normal sodium. Left ventricular function, left ventricular mass index (LVMI), the content of brain natriuretic peptide (BNP) in plasma and myocardium, myocardial hydroxyproline and heme oxygenase activity were determined after 6 weeks. The results showed that rats in model group developed significant cardiac hypertrophy associated with reduced left ventricular function compared with the control group. However, compared with the model group, L-NNA-induced cardiac hypertrophy of rats was significantly relieved in simvastatin treatment groups, associated with improved left ventricular function, decreased LVMI, lower BNP levels in plasma and myocardium, lower content of myocardial hydroxyproline, and increased myocardial heme oxygenase (HO) activity. In cultured rat neonatal cardiomyocytes, simvastatin (30 or 100 mumol/L) significantly increased heme oxygenase-1 (HO-1) mRNA expression, HO activity as well as the production of CO in cardiomyocytes. Cultured with zinc protoporphyrin, a HO inhibitor, or simvastatin alone did not change [(3)H]leucine uptake of cardiomyocytes. However, cocultured with simvastatin significantly inhibited the cardiomyocyte [(3)H]leucine uptake induced by angiotensin II in a concentration-dependent manner. Cotreatment with zinc protoporphyrin significantly abolished the suppressive effect of simvastatin on cardiomyocyte [(3)H]leucine uptake. These data suggest that the activation of HO-1/CO pathway may be one of the important mechanisms by which statins inhibit cardiac hypertrophy caused by hypertension.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yao</LastName>
                    <ForeName>Hai-Mu</ForeName>
                    <Initials>HM</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Cardiology, Beijing Anzhen Hospital, Capital University of Medical Science, Beijing 100029, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Wu</LastName>
                    <ForeName>Xue-Si</ForeName>
                    <Initials>XS</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Geng</LastName>
                    <ForeName>Bin</ForeName>
                    <Initials>B</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tang</LastName>
                    <ForeName>Chao-Shu</ForeName>
                    <Initials>CS</Initials>
                </Author>
            </AuthorList>
            <Language>chi</Language>
            <PublicationTypeList>
                <PublicationType UI="D004740">English Abstract</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>China</Country>
            <MedlineTA>Sheng Li Xue Bao</MedlineTA>
            <NlmUniqueID>20730130R</NlmUniqueID>
            <ISSNLinking>0371-0874</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000809">Angiotensins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>7U1EE4V452</RegistryNumber>
                <NameOfSubstance UI="D002248">Carbon Monoxide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>AGG2FN16EV</RegistryNumber>
                <NameOfSubstance UI="D019821">Simvastatin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 1.14.99.3</RegistryNumber>
                <NameOfSubstance UI="D051547">Heme Oxygenase-1</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000809">Angiotensins</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002248">Carbon Monoxide</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006332">Cardiomegaly</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D049108">Cell Enlargement</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051547">Heme Oxygenase-1</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006973">Hypertension</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D032383">Myocytes, Cardiac</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000166">cytology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D019821">Simvastatin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2013</Year>
                <Month>12</Month>
                <Day>20</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2006</Year>
                <Month>4</Month>
                <Day>22</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">16628357</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">19539102</PMID>
        <DateCreated>
            <Year>2009</Year>
            <Month>06</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2009</Year>
            <Month>08</Month>
            <Day>28</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0149-2918</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>31</Volume>
                    <Issue>5</Issue>
                    <PubDate>
                        <Year>2009</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical therapeutics</Title>
                <ISOAbbreviation>Clin Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection.</ArticleTitle>
            <Pagination>
                <MedlinePgn>1014-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.clinthera.2009.05.012</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The diagnosis of drug-induced liver injury relies on comprehensive clinical assessments due to the absence of an established biomarker or pathognomonic features of liver histology. However, prompt recognition of a culprit drug as the cause of liver injury is the most important aspect in the management of hepatotoxicity.</AbstractText>
                <AbstractText Label="CASE SUMMARY" NlmCategory="METHODS">A 63-year-old white male (85 kg) was admitted because of community-acquired pneumonia with associated pericarditis and subclinical hepatitis, subsequently related to acute Mycoplasma pneumoniae infection (diagnostic positive immuno-globulin M enzyme immunoassay, on hospital days 5 and 20). The patient had received cisplatin and radiotherapy from March to May 2006, as treatment for pharyngolaryngeal squamous cell carcinoma T3N0M0 without subsequent evidence of localized or meta-static recurrent disease (last oncologic consultation, May 17, 2007). He reported alcohol ingestion until March 2006 but no known liver disease, blood transfusion, or exposure to mushrooms or industrial cleaning solvents. Results of serologic tests for viral and nonviral infectious hepatitis, iron and copper studies, and tests for autoantibodies were normal or negative. The patient became initially asymptomatic and fever disappeared following sequential treatment with levo-floxacin (500 mg BID), doxycycline (100 mg BID), and naproxen (500 mg TID). However, on hospital day 10 jaundice and a significant elevation (alanine aminotransferase, 1577 U/L; aspartate amino-transferase, 1754 U/L; alkaline phosphatase, 189 U/L) of serum transaminases appeared. Despite the discontinuation of all medication, the patient gradually deteriorated and died 27 days after admission due to acute fulminant hepatic failure. Autopsy revealed massive hepatic necrosis, inflammatory changes with presence of eosinophils, and cholestasis. An objective causality assessment scale (Council for International Organizations of Medical Sciences/Roussel Uclaf Causality Assessment Method scale) suggested that each of the 3 drugs could &quot;probably&quot; (score = 6) be related to the patient's fulminant hepatitis. The Naranjo Adverse Drug Reactions Probability Scale assessment for the same drugs indicated a &quot;possible&quot; causal relation (score = 2).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We report a case of lethal hepatitis possibly/probably associated with levofloxacin, doxy-cycline, and naproxen in a patient with acute M pneumoniae infection.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Carrascosa</LastName>
                    <ForeName>Miguel F</ForeName>
                    <Initials>MF</Initials>
                    <AffiliationInfo>
                        <Affiliation>Internal Medicine Department, Hospital of Laredo, Cantabria, Spain. mcarrascosa@hlrd.scsalud.es</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lucena</LastName>
                    <ForeName>María Isabel</ForeName>
                    <Initials>MI</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Andrade</LastName>
                    <ForeName>Raúl J</ForeName>
                    <Initials>RJ</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Caviedes</LastName>
                    <ForeName>José Ramón S</ForeName>
                    <Initials>JR</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lavín</LastName>
                    <ForeName>Antonio C</ForeName>
                    <Initials>AC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Mones</LastName>
                    <ForeName>Juan C</ForeName>
                    <Initials>JC</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Rivero</LastName>
                    <ForeName>Andrea P</ForeName>
                    <Initials>AP</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Serrano</LastName>
                    <ForeName>Vicente B</ForeName>
                    <Initials>VB</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D002363">Case Reports</PublicationType>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Ther</MedlineTA>
            <NlmUniqueID>7706726</NlmUniqueID>
            <ISSNLinking>0149-2918</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>57Y76R9ATQ</RegistryNumber>
                <NameOfSubstance UI="D009288">Naproxen</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>6GNT3Y5LMF</RegistryNumber>
                <NameOfSubstance UI="D064704">Levofloxacin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>A4P49JAZ9H</RegistryNumber>
                <NameOfSubstance UI="D015242">Ofloxacin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>N12000U13O</RegistryNumber>
                <NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000208">Acute Disease</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000900">Anti-Bacterial Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004318">Doxycycline</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056486">Drug-Induced Liver Injury</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017809">Fatal Outcome</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006505">Hepatitis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D064704">Levofloxacin</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017114">Liver Failure, Acute</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000139">chemically induced</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008875">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009288">Naproxen</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015242">Ofloxacin</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000009">adverse effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010493">Pericarditis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D011019">Pneumonia, Mycoplasma</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="accepted">
                <Year>2009</Year>
                <Month>4</Month>
                <Day>14</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2009</Year>
                <Month>6</Month>
                <Day>23</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2009</Year>
                <Month>8</Month>
                <Day>29</Day>
                <Hour>9</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pii">S0149-2918(09)00158-1</ArticleId>
            <ArticleId IdType="doi">10.1016/j.clinthera.2009.05.012</ArticleId>
            <ArticleId IdType="pubmed">19539102</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12841644</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>07</Month>
            <Day>04</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2004</Year>
            <Month>04</Month>
            <Day>15</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0300-8177</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>247</Volume>
                    <Issue>1-2</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>May</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Molecular and cellular biochemistry</Title>
                <ISOAbbreviation>Mol. Cell. Biochem.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effect of L-arginine and L-lysine on lysosomal hydrolases and membrane bound phosphatases in experimentally induced myocardial infarction in rats.</ArticleTitle>
            <Pagination>
                <MedlinePgn>163-9</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>The protective effect of L-arginine and L-lysine on lysosomal enzymes and membrane bound ATPases was examined on isoproterenol induced myocardial infarction in rats. Lysosomal enzymes play an important role in the inflammatory process. The rats given isoproterenol (150 mg kg(-1) daily) intraperitoneally for 2 days showed significant changes in the marker enzymes, lysosomal enzymes and membrane bound phosphatases. Histopathological studies also confirmed the induction of myocardial infarction in isoproterenol administered rats. Prior oral treatment with L-arginine (250 mg kg(-1) daily) and L-lysine (5 mg kg(-1) daily) for 5 days significantly prevented these alterations and restored the enzyme activities to near normal. These findings demonstrate the protective effect of L-arginine and L-lysine in combination against isoproterenol induced cardiac damage.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Ebenezar</LastName>
                    <ForeName>Kesavarao Kumar</ForeName>
                    <Initials>KK</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Biochemistry and Molecular Biology, University of Madras, Guindy Campus, Chennai, Tamilnadu, India.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Sathish</LastName>
                    <ForeName>Venkatachalem</ForeName>
                    <Initials>V</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Devaki</LastName>
                    <ForeName>Thiruvengadam</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Mol Cell Biochem</MedlineTA>
            <NlmUniqueID>0364456</NlmUniqueID>
            <ISSNLinking>0300-8177</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>94ZLA3W45F</RegistryNumber>
                <NameOfSubstance UI="D001120">Arginine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.-</RegistryNumber>
                <NameOfSubstance UI="D006867">Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.1.3.-</RegistryNumber>
                <NameOfSubstance UI="D010744">Phosphoric Monoester Hydrolases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>K3Z4F929H6</RegistryNumber>
                <NameOfSubstance UI="D008239">Lysine</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>L628TT009W</RegistryNumber>
                <NameOfSubstance UI="D007545">Isoproterenol</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001120">Arginine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002462">Cell Membrane</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004195">Disease Models, Animal</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006867">Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007545">Isoproterenol</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000633">toxicity</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008239">Lysine</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008247">Lysosomes</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009203">Myocardial Infarction</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000139">chemically induced</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000201">enzymology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009206">Myocardium</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010744">Phosphoric Monoester Hydrolases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000187">drug effects</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051381">Rats</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017208">Rats, Wistar</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012016">Reference Values</DescriptorName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>7</Month>
                <Day>5</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2004</Year>
                <Month>4</Month>
                <Day>16</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>7</Month>
                <Day>5</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12841644</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">23843956</PMID>
        <DateCreated>
            <Year>2013</Year>
            <Month>07</Month>
            <Day>11</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2014</Year>
            <Month>01</Month>
            <Day>23</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Electronic-Print">
            <Journal>
                <ISSN IssnType="Electronic">1932-6203</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>8</Volume>
                    <Issue>7</Issue>
                    <PubDate>
                        <Year>2013</Year>
                    </PubDate>
                </JournalIssue>
                <Title>PloS one</Title>
                <ISOAbbreviation>PLoS ONE</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Novel ATPase Cu(2+) transporting beta polypeptide mutations in Chinese families with Wilson's disease.</ArticleTitle>
            <Pagination>
                <MedlinePgn>e66526</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0066526</ELocationID>
            <Abstract>
                <AbstractText>Wilson's disease (WD) is an autosomal recessive inherited disorder caused by mutations in the ATPase Cu(2+) transporting beta polypeptide gene (ATP7B). The detailed metabolism of copper-induced pathology in WD is still unknown. Gene mutations as well as the possible pathways involved in the ATP7B deficiency were documented. The ATP7B gene was analyzed for mutations in 18 Chinese Han families with WD by direct sequencing. Cell viability and apoptosis analysis of ATP7B small interfering RNA (siRNA)-treated human liver carcinoma (HepG2) cells were measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay and Hoechst 33342 staining. Finally, the expression of B-cell CLL/lymphoma 2 (BCL2), BCL2-associated X protein (BAX), sterol regulatory element binding protein 1 (SREBP1), and minichromosome maintenance protein 7 (MCM7) of ATP7B siRNA-treated cells were tested by real-time polymerase chain reaction (real-time PCR) and Western blot analysis. Twenty different mutations including four novel mutations (p.Val145Phe, p.Glu388X, p.Thr498Ser and p.Gly837X) in the ATP7B gene were identified in our families. Haplotype analysis revealed that founder effects for four mutations (p.Arg778Leu, p.Pro992Leu, p.Ile1148Thr and p.Ala1295Val) existed in these families. Transfection of HepG2 cells with ATP7B siRNA resulted in decreased mRNA expression by 86.3%, 93.1% and 90.8%, and decreased protein levels by 58.5%, 85.5% and 82.1% at 24, 48 and 72 hours, respectively (All P&lt;0.01). In vitro study revealed that the apoptotic, cell cycle and lipid metabolism pathway may be involved in the mechanism of WD. Our results revealed that the genetic cause of 18 Chinese families with WD and ATP7B deficiency-induce apoptosis may result from imbalance in cell cycle and lipid metabolism pathway.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Gu</LastName>
                    <ForeName>Shaojuan</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Center for Experimental Medicine, the Third Xiangya Hospital, Central South University, Changsha, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Huarong</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Qi</LastName>
                    <ForeName>Yong</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deng</LastName>
                    <ForeName>Xiong</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Le</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Guo</LastName>
                    <ForeName>Yi</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Qing</ForeName>
                    <Initials>Q</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Jing</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shi</LastName>
                    <ForeName>Xiaoliu</ForeName>
                    <Initials>X</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Zhi</ForeName>
                    <Initials>Z</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Deng</LastName>
                    <ForeName>Hao</ForeName>
                    <Initials>H</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2013</Year>
                <Month>07</Month>
                <Day>02</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>PLoS One</MedlineTA>
            <NlmUniqueID>101285081</NlmUniqueID>
            <ISSNLinking>1932-6203</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C494826">BAX protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D027682">Cation Transport Proteins</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D034741">RNA, Small Interfering</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C497387">SREBF1 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051780">Sterol Regulatory Element Binding Protein 1</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D050998">bcl-2 Homologous Antagonist-Killer Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>789U1901C5</RegistryNumber>
                <NameOfSubstance UI="D003300">Copper</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.1.-</RegistryNumber>
                <NameOfSubstance UI="D000251">Adenosine Triphosphatases</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.3.4</RegistryNumber>
                <NameOfSubstance UI="C093154">Wilson disease protein</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.12</RegistryNumber>
                <NameOfSubstance UI="C101624">MCM7 protein, human</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.6.4.12</RegistryNumber>
                <NameOfSubstance UI="D064168">Minichromosome Maintenance Complex Component 7</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Hum Genet. 1997 Jun;60(6):1423-9</RefSource>
                <PMID Version="1">9199563</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 1998;Suppl 1:S320-2</RefSource>
                <PMID Version="1">9452121</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Met Ions Biol Syst. 1999;36:309-64</RefSource>
                <PMID Version="1">10093929</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Genet. 2005 Jul;68(1):61-8</RefSource>
                <PMID Version="1">15952988</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mol Genet Metab. 2005 Sep-Oct;86(1-2):277-85</RefSource>
                <PMID Version="1">15967699</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Genet. 2005 Dec;68(6):524-32</RefSource>
                <PMID Version="1">16283883</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2007 Mar 16;282(11):8343-55</RefSource>
                <PMID Version="1">17205981</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Neurol. 2007 Mar;64(3):421-4</RefSource>
                <PMID Version="1">17353387</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2007 Dec;28(12):1171-7</RefSource>
                <PMID Version="1">17680703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hum Genet. 2008;53(1):55-63</RefSource>
                <PMID Version="1">18034201</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2009 Mar;50(3):555-61</RefSource>
                <PMID Version="1">19118915</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Clin Cancer Res. 2009 Jun 1;15(11):3770-80</RefSource>
                <PMID Version="1">19470734</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Lung Cancer. 2009 Aug;65(2):223-9</RefSource>
                <PMID Version="1">19144445</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hepatology. 2009 Nov;50(5):1442-52</RefSource>
                <PMID Version="1">19731238</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Proteome Res. 2010 Jan;9(1):485-94</RefSource>
                <PMID Version="1">19877719</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Curr Gastroenterol Rep. 2010 Feb;12(1):57-61</RefSource>
                <PMID Version="1">20425485</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Gastroenterol. 2010 Jul;44(6):387-8</RefSource>
                <PMID Version="1">20421802</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Gastroenterol. 2010 Jul;44(6):432-9</RefSource>
                <PMID Version="1">20485189</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Biol Chem. 2010 Oct 1;285(40):30875-83</RefSource>
                <PMID Version="1">20647314</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mod Pathol. 2011 Feb;24(2):277-87</RefSource>
                <PMID Version="1">21076460</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cancer. 2011 May 15;117(10):2067-76</RefSource>
                <PMID Version="1">21523718</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Hepatol. 2011 Oct;55(4):913-9</RefSource>
                <PMID Version="1">21334398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Mamm Genome. 2011 Dec;22(11-12):703-13</RefSource>
                <PMID Version="1">21997183</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Cell Mol Biol (Noisy-le-grand). 2000 Jun;46(4):731-41</RefSource>
                <PMID Version="1">10875436</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur J Neurol. 2000 Sep;7(5):491-4</RefSource>
                <PMID Version="1">11054132</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Nutr. 2000 Dec;130(12):2915-21</RefSource>
                <PMID Version="1">11110846</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Liver Int. 2003 Jun;23(3):139-42</RefSource>
                <PMID Version="1">12955875</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Mutat. 2004 Apr;23(4):398</RefSource>
                <PMID Version="1">15024742</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000251">Adenosine Triphosphatases</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D044466">Asian Continental Ancestry Group</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D027682">Cation Transport Proteins</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002453">Cell Cycle</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002470">Cell Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003300">Copper</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004252">DNA Mutational Analysis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005786">Gene Expression Regulation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D056945">Hep G2 Cells</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006527">Hepatolenticular Degeneration</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000208">ethnology</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050356">Lipid Metabolism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D064168">Minichromosome Maintenance Complex Component 7</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D009154">Mutation</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D034741">RNA, Small Interfering</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015398">Signal Transduction</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051780">Sterol Regulatory Element Binding Protein 1</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D050998">bcl-2 Homologous Antagonist-Killer Protein</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051028">bcl-2-Associated X Protein</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000235">genetics</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
        <OtherID Source="NLM">PMC3699604</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="ppublish">
                <Year>2013</Year>
                <Month/>
                <Day/>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="received">
                <Year>2013</Year>
                <Month>3</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2013</Year>
                <Month>5</Month>
                <Day>6</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="epublish">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>2</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2013</Year>
                <Month>7</Month>
                <Day>12</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2014</Year>
                <Month>1</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>epublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0066526</ArticleId>
            <ArticleId IdType="pii">PONE-D-13-08891</ArticleId>
            <ArticleId IdType="pubmed">23843956</ArticleId>
            <ArticleId IdType="pmc">PMC3699604</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">903216</PMID>
        <DateCreated>
            <Year>1977</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCreated>
        <DateCompleted>
            <Year>1977</Year>
            <Month>11</Month>
            <Day>25</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2014</Year>
            <Month>11</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0021-0005</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>15</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>1977</Year>
                        <Month>Sep</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Investigative urology</Title>
                <ISOAbbreviation>Invest Urol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Inhibition of urease by miscellaneous ions and compounds. Implications for the therapy of infection-induced urolithiasis.</ArticleTitle>
            <Pagination>
                <MedlinePgn>180-2</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>One hundred forty-eight drugs and other organic and inorganic substances were screened for their ability to inhibit the enzyme urease in an in vitro system modeled on infected urine. The reported urease-inhibiting properties of ascorbic acid, tetracyclines, and sulfanilamide were not confirmed. At least 50 per cent inhibition was observed in the presence of kanamvcin, hydroxguanidine, benzoquinone, 1,2-naphthaquinone-4-sulfonate, chloramine-T, N-bromoacetamide, copper, mercury, and fluoride. It is, however, unlikely that therapeutically effective concentrations can be attained in urine without giving dosages likely to result in toxic effects. Hydroxyurea, at the dose level used in cytotoxic therapy, may be expected to produce effective inhibition of bacterial urease in the urinary tract, providing renal function is unimpaired and providing urinary volume does not exceed 1 liter per 24 hr. Acetohydroxamic acid is potentially the most useful drug for the treatment of infection-induced urinary stone disease available at present.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Burr</LastName>
                    <ForeName>R G</ForeName>
                    <Initials>RG</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>UNITED STATES</Country>
            <MedlineTA>Invest Urol</MedlineTA>
            <NlmUniqueID>0374747</NlmUniqueID>
            <ISSNLinking>0021-0005</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D006877">Hydroxamic Acids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D007477">Ions</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D013424">Sulfanilamides</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>59-01-8</RegistryNumber>
                <NameOfSubstance UI="D007612">Kanamycin</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>EC 3.5.1.5</RegistryNumber>
                <NameOfSubstance UI="D014510">Urease</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>X6Q56QN5QC</RegistryNumber>
                <NameOfSubstance UI="D006918">Hydroxyurea</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001424">Bacterial Infections</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006877">Hydroxamic Acids</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006918">Hydroxyurea</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D066298">In Vitro Techniques</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007477">Ions</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007612">Kanamycin</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013424">Sulfanilamides</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014510">Urease</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000037">antagonists &amp; inhibitors</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014545">Urinary Calculi</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>1977</Year>
                <Month>9</Month>
                <Day>1</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>1977</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>1977</Year>
                <Month>9</Month>
                <Day>1</Day>
                <Hour>0</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">903216</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">11166288</PMID>
        <DateCreated>
            <Year>2001</Year>
            <Month>02</Month>
            <Day>22</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2001</Year>
            <Month>05</Month>
            <Day>10</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>11</Month>
            <Day>21</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">0014-2999</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>412</Volume>
                    <Issue>3</Issue>
                    <PubDate>
                        <Year>2001</Year>
                        <Month>Feb</Month>
                        <Day>2</Day>
                    </PubDate>
                </JournalIssue>
                <Title>European journal of pharmacology</Title>
                <ISOAbbreviation>Eur. J. Pharmacol.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys.</ArticleTitle>
            <Pagination>
                <MedlinePgn>247-54</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>(S)-(-)-3-(3-(methylsulfonyl)phenyl)-1-propylpiperidine ((-)-OSU6162) is a phenylpiperidine derivative which exhibits low affinity to the dopamine D2 receptor in vitro. However, in vivo, positron emission tomography scanning studies show that the compound displaces the selective dopamine D2 receptor antagonist, raclopride. We have evaluated, in this study, the effect of (-)-OSU6162, on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a primate model of Parkinson's disease. Five 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated cynomolgus monkeys with a stable parkinsonian syndrome and reproducible dyskinesias to L-DOPA were used in this study. The monkeys were housed in observation cages equipped with an electronic motility monitoring system. They were injected subcutaneously (s.c.) with L-DOPA methyl ester (125 mg per animal) plus benserazide (50 mg per animal; L-DOPA/benserazide) alone or in combination with (-)-OSU6162 (1.0, 3.0, 6.0 or 10 mg/kg, s.c.). Subcutaneous injection of sterile saline was used as control. L-DOPA/benserazide increased locomotion and improved parkinsonism but also induced dyskinesias. Co-administration of (-)-OSU6162 with L-DOPA/benserazide produced a significant reduction in L-DOPA-induced dyskinesias. This improvement in L-DOPA-induced dyskinesias occurred mainly at the onset of the L-DOPA/benserazide effect as reflected by an increase in the duration of the &quot;ON&quot; state without dyskinesias up to 3.4 fold after (-)-OSU6162 co-administration as compared to L-DOPA/benserazide alone. The anti-dyskinetic effect of (-)-OSU6162 was maintained during 14 days and no tolerance to this effect was observed. Our data suggests that (-)-OSU6162 could be of significant clinical value to reduce L-DOPA-induced dyskinesias in fluctuating advanced Parkinson's disease patients.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Hadj Tahar</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>Neuroscience Research Unit (RC-9800), CHUL, Laval University Research Center, 2705 Boul. Laurier, G1V 4G2, Ste.-Foy, Quebec, Canada.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Ekesbo</LastName>
                    <ForeName>A</ForeName>
                    <Initials>A</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Grégoire</LastName>
                    <ForeName>L</ForeName>
                    <Initials>L</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bangassoro</LastName>
                    <ForeName>E</ForeName>
                    <Initials>E</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Svensson</LastName>
                    <ForeName>K A</ForeName>
                    <Initials>KA</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Tedroff</LastName>
                    <ForeName>J</ForeName>
                    <Initials>J</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Bédard</LastName>
                    <ForeName>P J</ForeName>
                    <Initials>PJ</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Eur J Pharmacol</MedlineTA>
            <NlmUniqueID>1254354</NlmUniqueID>
            <ISSNLinking>0014-2999</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D018492">Dopamine Antagonists</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="C109513">OSU 6162</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D017448">Receptors, Dopamine D2</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>46627O600J</RegistryNumber>
                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>762OS3ZEJU</RegistryNumber>
                <NameOfSubstance UI="D001545">Benserazide</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>9P21XSP91P</RegistryNumber>
                <NameOfSubstance UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015632">1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001545">Benserazide</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D018492">Dopamine Antagonists</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D005260">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000008">administration &amp; dosage</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008252">Macaca fascicularis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009043">Motor Activity</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000503">physiopathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D010880">Piperidines</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017448">Receptors, Dopamine D2</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2001</Year>
                <Month>5</Month>
                <Day>22</Day>
                <Hour>10</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2001</Year>
                <Month>2</Month>
                <Day>13</Day>
                <Hour>11</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">11166288</ArticleId>
            <ArticleId IdType="pii">S0014299901007373</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>


<PubmedArticle>
    <MedlineCitation Owner="NLM" Status="MEDLINE">
        <PMID Version="1">12576464</PMID>
        <DateCreated>
            <Year>2003</Year>
            <Month>02</Month>
            <Day>10</Day>
        </DateCreated>
        <DateCompleted>
            <Year>2003</Year>
            <Month>08</Month>
            <Day>01</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2013</Year>
            <Month>05</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Print">1078-0432</ISSN>
                <JournalIssue CitedMedium="Print">
                    <Volume>9</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <Year>2003</Year>
                        <Month>Feb</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Clinical cancer research : an official journal of the American Association for Cancer Research</Title>
                <ISOAbbreviation>Clin. Cancer Res.</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma.</ArticleTitle>
            <Pagination>
                <MedlinePgn>886-99</MedlinePgn>
            </Pagination>
            <Abstract>
                <AbstractText>We demonstrated recently that chronic frequent administration of an adequate biological dose of the angiogenesis inhibitor TNP-470 (AGM-1470, O-chloracetyl-carbamoyl fumagillol) completely inhibits spontaneous lymph node metastasis but does not have a complete response on tumor growth of nonestablished or established human metastatic transitional cell carcinoma (TCC) 253J B-V growing orthotopically into athymic nude mice. Therefore, in this study, we evaluated whether docetaxel (Taxotere) enhances the therapeutic effect of TNP-470, especially on tumor growth. Docetaxel enhanced in vitro antiproliferation but not basic fibroblast growth factor down-regulation by TNP-470 in 253J B-V and human umbilical vascular endothelial cells. Docetaxel significantly enhanced in vitro apoptosis by TNP-470 in human umbilical vascular endothelial cells but not in 253J B-V. In vivo combination was most effective when docetaxel was administered before TNP-470, and increased significantly the complete response on tumor growth of nonestablished and established TCCs growing orthotopically into athymic nude mice compared with either therapy alone (P &lt; 0.05). The incidence of spontaneous lymph node metastasis was inhibited completely by the combination therapy (P &lt; 0.05). Drug-induced body weight loss was not significantly different in any treatment groups. The combination of TNP-470 and docetaxel inhibited intratumor neovascularization, the expression of bFGF and matrix metalloproteinases type-9 compared with controls (P &lt; 0.005), and enhanced apoptosis in tumors compared with each therapy alone (P &lt; 0.005). These studies indicate that docetaxel markedly enhances the ability of TNP-470 to inhibit tumorigenicity and metastasis in both nonestablished and established TCCs. These effects are mediated, in part, by the complementary cytotoxicities of angiogenesis inhibition, down-regulation of bFGF and matrix metalloproteinases type-9, and induction of apoptosis.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Inoue</LastName>
                    <ForeName>Keiji</ForeName>
                    <Initials>K</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Urology, Kochi Medical School, Nankoku, Kochi 783-8505, Japan.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Chikazawa</LastName>
                    <ForeName>Masakazu</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Fukata</LastName>
                    <ForeName>Satoshi</ForeName>
                    <Initials>S</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Yoshikawa</LastName>
                    <ForeName>Chiaki</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Shuin</LastName>
                    <ForeName>Taro</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>Clin Cancer Res</MedlineTA>
            <NlmUniqueID>9502500</NlmUniqueID>
            <ISSNLinking>1078-0432</ISSNLinking>
        </MedlineJournalInfo>
        <ChemicalList>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D020533">Angiogenesis Inhibitors</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D003510">Cyclohexanes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D012717">Sesquiterpenes</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>0</RegistryNumber>
                <NameOfSubstance UI="D043823">Taxoids</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>129298-91-5</RegistryNumber>
                <NameOfSubstance UI="C066515">O-(chloroacetylcarbamoyl)fumagillol</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>15H5577CQD</RegistryNumber>
                <NameOfSubstance UI="C067311">docetaxel</NameOfSubstance>
            </Chemical>
            <Chemical>
                <RegistryNumber>33069-62-4</RegistryNumber>
                <NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance>
            </Chemical>
        </ChemicalList>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D020533">Angiogenesis Inhibitors</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D000818">Animals</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017209">Apoptosis</DescriptorName>
                <QualifierName MajorTopicYN="N" UI="Q000187">drug effects</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D002295">Carcinoma, Transitional Cell</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000098">blood supply</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D003510">Cyclohexanes</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D004357">Drug Synergism</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D051379">Mice</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008807">Mice, Inbred BALB C</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D008819">Mice, Nude</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009362">Neoplasm Metastasis</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D009389">Neovascularization, Pathologic</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000517">prevention &amp; control</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D017239">Paclitaxel</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000031">analogs &amp; derivatives</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D012717">Sesquiterpenes</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="Y" UI="D043823">Taxoids</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D013997">Time Factors</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D014183">Transplantation, Heterologous</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName MajorTopicYN="N" UI="D001749">Urinary Bladder Neoplasms</DescriptorName>
                <QualifierName MajorTopicYN="Y" UI="Q000098">blood supply</QualifierName>
                <QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
                <QualifierName MajorTopicYN="N" UI="Q000473">pathology</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2003</Year>
                <Month>8</Month>
                <Day>2</Day>
                <Hour>5</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2003</Year>
                <Month>2</Month>
                <Day>11</Day>
                <Hour>4</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">12576464</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
